{
    "items": "157",
    "sentiment_score_definition": "x <= -0.35: Bearish; -0.35 < x <= -0.15: Somewhat-Bearish; -0.15 < x < 0.15: Neutral; 0.15 <= x < 0.35: Somewhat_Bullish; x >= 0.35: Bullish",
    "relevance_score_definition": "0 < x <= 1, with a higher score indicating higher relevance.",
    "feed": [
        {
            "title": "An Important History Lesson for Gene-Editing Investors",
            "url": "https://www.fool.com/investing/2023/12/02/an-important-history-lesson-for-gene-editing-inves/",
            "time_published": "20231202T133000",
            "authors": [
                "George Budwell"
            ],
            "summary": "Gene editing holds tremendous promise for patients and investors alike. But the road to success won't be easy.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756820%2Fbiotech-researcher.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.127419,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "TRMNF",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "-0.095989",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081276",
                    "ticker_sentiment_score": "0.096784",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.115922",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.050122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.094399",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.040691",
                    "ticker_sentiment_score": "0.050122",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "-0.003598",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Eli Lilly a Better Stock to Buy and Hold Over the Next 10 Years Than Novo Nordisk?",
            "url": "https://www.fool.com/investing/2023/12/02/eli-lilly-better-stock-buy-hold-novo-nordisk/",
            "time_published": "20231202T105300",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Both of these stocks have been big winners this year. But one could be better positioned to extend that winning streak over the next decade.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756714/scientist-in-lab-young-african-american-female.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.576289"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.193651,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.669232",
                    "ticker_sentiment_score": "0.291227",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.450496",
                    "ticker_sentiment_score": "0.288295",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "5 Top Stocks to Buy Before 2024",
            "url": "https://www.fool.com/investing/2023/12/02/5-top-stocks-to-buy-before-2024/",
            "time_published": "20231202T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "These stocks have room to run -- next year and over the long term.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756622%2Fgettyimages-1323758599.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                }
            ],
            "overall_sentiment_score": 0.309374,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.223522",
                    "ticker_sentiment_score": "0.23701",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.147665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ISRG",
                    "relevance_score": "0.075397",
                    "ticker_sentiment_score": "0.285192",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.259529",
                    "ticker_sentiment_score": "0.252343",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Jaypirca®  ( pirtobrutinib )  Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Who Have Received at Least Two Lines of Therapy, Including a BTK Inhibitor and a BCL-2 Inhibitor",
            "url": "https://www.prnewswire.com/news-releases/jaypirca-pirtobrutinib-now-approved-by-us-fda-for-the-treatment-of-adult-patients-with-chronic-lymphocytic-leukemia-or-small-lymphocytic-lymphoma-who-have-received-at-least-two-lines-of-therapy-including-a-btk-inhibitor-and--302003695.html",
            "time_published": "20231201T222200",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "Jaypirca® ( pirtobrutinib ) Now Approved by U.S. FDA for the Treatment of Adult Patients with Chronic Lymphocytic ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": -0.036345,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.088187",
                    "ticker_sentiment_score": "0.076627",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.011046",
                    "ticker_sentiment_score": "0.149713",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs And Associated Suicidal Thoughts - European Drug Regulator Seeks Clarifications From Drug Makers - AstraZeneca  ( NASDAQ:AZN ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36046376/weight-loss-drugs-and-associated-suicidal-thoughts-european-drug-regulator-seeks-clarifications-f",
            "time_published": "20231201T174334",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "European Medicines Agency ( EMA ) will request further clarifications from drugmakers of GLP-1 receptor agonists for diabetes and weight loss, including Novo Nordisk A/S's NVO popular therapies Ozempic and Wegovy, to investigate suicidal thoughts further.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.113612,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "-0.211382",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.297661",
                    "ticker_sentiment_score": "0.198834",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why investors should stick with Eli Lilly",
            "url": "https://www.cnbc.com/2023/12/01/why-investors-should-stick-with-eli-lilly-.html",
            "time_published": "20231201T162656",
            "authors": [
                "Jeff Marks"
            ],
            "summary": "The Investing Club holds its Morning Meeting every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107341967-17014449221701444917-32264211645-1080pnbcnews.jpg?v=1701444921&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.261976,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.2673",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "STZ",
                    "relevance_score": "0.338582",
                    "ticker_sentiment_score": "0.2673",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.087185",
                    "ticker_sentiment_score": "0.117665",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.173333",
                    "ticker_sentiment_score": "0.160996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Annovis Bio  ( ANVS )  Stock Surges 38% in a Month: Here's Why",
            "url": "https://www.zacks.com/stock/news/2192301/annovis-bio-anvs-stock-surges-38-in-a-month-heres-why",
            "time_published": "20231201T161200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Annovis' (ANVS) shares surge on the successful development of its lead candidate in Alzheimer's disease.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/21/594.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.132141,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.235366",
                    "ticker_sentiment_score": "0.116995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTMX",
                    "relevance_score": "0.235366",
                    "ticker_sentiment_score": "0.069513",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANVS",
                    "relevance_score": "0.324902",
                    "ticker_sentiment_score": "0.006998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.142565",
                    "ticker_sentiment_score": "0.146836",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight Loss Drugs - Novo Nordisk A Primary Beneficiary In Obesity Space Currently Controlled By Two Players, Says Analyst - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/12/36044511/weight-loss-drugs-novo-nordisk-a-primary-beneficiary-in-obesity-space-currently-controlled-by-two",
            "time_published": "20231201T155549",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Cantor Fitzgerald has initiated coverage on Europe's most valuable company, Novo Nordisk A/S NVO. The analyst says the runway for obesity will remain attractive for years to come, and Novo Nordisk will be an outsized beneficiary of this trend, given its leadership in the space where it competes ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/12/01/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.335612,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.282234",
                    "ticker_sentiment_score": "0.273657",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.721785",
                    "ticker_sentiment_score": "0.664621",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "PFE Stock Slides After Pfizer's Latest Setback For Weight-Loss Drug",
            "url": "https://www.investors.com/news/technology/pfe-stock-slides-after-pfizers-latest-setback-for-weight-loss-drug/",
            "time_published": "20231201T154200",
            "authors": [
                "RYAN DEFFENBAUGH",
                "Investor's Business Daily"
            ],
            "summary": "Pfizer ( PFE ) said Friday it would not advance development of a twice-daily oral weight-loss drug because of its side effects. PFE stock fell in early trading, as the company said it would focus on a once-daily version of the drug.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2022/01/Stock-pfizersign-05-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.989041"
                }
            ],
            "overall_sentiment_score": -0.016787,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.025896",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.317527",
                    "ticker_sentiment_score": "0.114072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.898236",
                    "ticker_sentiment_score": "-0.075898",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Dow Hits 2023 High; Cybertruck Deliveries Begin: Weekly Review",
            "url": "https://www.investors.com/news/dow-jones-hits-2023-high-nasdaq-slips-tesla-cybertruck-salesforce-in-focus-weekly-review/",
            "time_published": "20231201T153300",
            "authors": [
                "IBD STAFF",
                "Investor's Business Daily"
            ],
            "summary": "Dow Hits '23 High, Nasdaq Slips. Cybertruck Debuts: Weekly Review Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-cybertruck-new-01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.033931,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "IMVT",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.072731",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PATH",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.023254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FRO",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.101281",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.015905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.021857",
                    "ticker_sentiment_score": "0.075399",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.158559",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.029968",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DTST",
                    "relevance_score": "0.021857",
                    "ticker_sentiment_score": "0.062006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTAP",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.066641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.142486",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PSTG",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "0.070487",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.130571",
                    "ticker_sentiment_score": "-0.020666",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JBL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.027781",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.065377",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.186514",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BABA",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.139972",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.047801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.070753",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.049762",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "-0.086479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.029",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDAY",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "0.003043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IOT",
                    "relevance_score": "0.108958",
                    "ticker_sentiment_score": "0.091975",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTNX",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.032738",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPS",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.188661",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.087265",
                    "ticker_sentiment_score": "0.147331",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.065506",
                    "ticker_sentiment_score": "-0.073733",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "0.070395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.017503",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.043698",
                    "ticker_sentiment_score": "-0.002991",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Underrated Reason to Buy Eli Lilly Stock",
            "url": "https://www.fool.com/investing/2023/12/01/1-underrated-reason-to-buy-eli-lilly-stock/",
            "time_published": "20231201T144500",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Eli Lilly has a well-rounded business that can be a good fit for all types of investors.",
            "banner_image": "https://media.ycharts.com/charts/222a363a44940e5b07e73a2947efb7f9.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.77141"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.723405"
                }
            ],
            "overall_sentiment_score": 0.327042,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.496741",
                    "ticker_sentiment_score": "0.468567",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "If You Invested $100 In This Stock 10 Years Ago, You Would Have $1,200 Today - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/12/36044018/if-you-invested-100-in-this-stock-10-years-ago-you-would-have-1-200-today",
            "time_published": "20231201T143024",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly LLY has outperformed the market over the past 10 years by 18.16% on an annualized basis producing an average annual return of 27.95%. Currently, Eli Lilly has a market capitalization of $557.96 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.375984",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( LLY )  Is a Trending Stock: Facts to Know Before Betting on It",
            "url": "https://www.zacks.com/stock/news/2192122/eli-lilly-and-company-lly-is-a-trending-stock-facts-to-know-before-betting-on-it",
            "time_published": "20231201T140010",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Recently, Zacks.com users have been paying close attention to Lilly (LLY). This makes it worthwhile to examine what the stock has in store.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default323.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.54554"
                }
            ],
            "overall_sentiment_score": 0.239417,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.529767",
                    "ticker_sentiment_score": "0.154338",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: ABBV to Buy Immunogen, NVS Ups Mid-Term Sales View & More",
            "url": "https://www.zacks.com/stock/news/2192051/pharma-stock-roundup-abbv-to-buy-immunogen-nvs-ups-mid-term-sales-view-more",
            "time_published": "20231201T131300",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "AbbVie (ABBV) offers to acquire cancer biotech Immunogen for $10.1 billion. Novartis (NVS) raises its mid-term sales growth outlook by 1%.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f2/4113.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.163367,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "-0.015264",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IMGN",
                    "relevance_score": "0.187317",
                    "ticker_sentiment_score": "0.040964",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.259925",
                    "ticker_sentiment_score": "0.075641",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "-0.016291",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.0378",
                    "ticker_sentiment_score": "-0.115845",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.08342",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "December Looks Great For Investors Who Own 9 Stocks",
            "url": "https://www.investors.com/etfs-and-funds/sectors/sp500-december-looks-great-for-investors-who-own-stocks/",
            "time_published": "20231201T130000",
            "authors": [
                "Investor's Business Daily",
                "MATT KRANTZ"
            ],
            "summary": "Investors can only hope stocks do as well in December as they did in November. There are definitely some S&P 500 stocks that glisten in the last month of the year.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-december-02-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.217163,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BKR",
                    "relevance_score": "0.195025",
                    "ticker_sentiment_score": "0.314614",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.273927",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SWKS",
                    "relevance_score": "0.288893",
                    "ticker_sentiment_score": "0.262842",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Pfizer's stock falls 4% after halting trial of obesity drug due to side effects",
            "url": "https://www.marketwatch.com/story/pfizers-stock-falls-4-after-saying-it-will-not-move-to-phase-3-trial-of-weight-loss-drug-as-twice-daily-formation-3813e092",
            "time_published": "20231201T115800",
            "authors": [
                "Ciara Linnane"
            ],
            "summary": "Pfizer's drug helped patients lose weight but also caused nausea and diarrhea.",
            "banner_image": "https://images.mktw.net/im-267059/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158314,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.23281",
                    "ticker_sentiment_score": "0.324495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.23281",
                    "ticker_sentiment_score": "0.324495",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.44622",
                    "ticker_sentiment_score": "0.136681",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "AbbVie  ( ABBV )  to Acquire ImmunoGen  ( IMGN )  for $10.1 Billion",
            "url": "https://www.zacks.com/stock/news/2191954/abbvie-abbv-to-acquire-immunogen-imgn-for-101-billion",
            "time_published": "20231201T105500",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "AbbVie (ABBV) offers to buy ImmunoGen (IMGN) for approximately $10.1 billion, which will diversify its oncology pipeline across solid tumors and hematologic malignancies.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.108674,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.138066",
                    "ticker_sentiment_score": "-0.129917",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.398148",
                    "ticker_sentiment_score": "0.224559",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "-0.106663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRTX",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "0.088905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.069294",
                    "ticker_sentiment_score": "-0.106663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BMY",
                    "relevance_score": "0.138066",
                    "ticker_sentiment_score": "0.112347",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Biotech Stock Nears A Buy Point After 200% Profit Growth",
            "url": "https://www.investors.com/stock-lists/sector-leaders/this-biotech-stock-nears-a-buy-point-after-profit-growth/",
            "time_published": "20231130T231300",
            "authors": [
                "KIMBERLEY KOENIG",
                "Investor's Business Daily"
            ],
            "summary": "Biotech Amphastar Pharmaceuticals ( AMPH ) sits in a base after a big earnings move and is poised for a breakout. The IBD Sector Leader gained around 24% since its earnings report in early November. Amphastar Pharmaceuticals develops injectable, inhalation and intranasal medical products.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/06/Stock-amphastarpharma-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.996675"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986714"
                }
            ],
            "overall_sentiment_score": 0.316705,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.172713",
                    "ticker_sentiment_score": "-0.138974",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMPH",
                    "relevance_score": "0.48724",
                    "ticker_sentiment_score": "0.31807",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why Is Incyte  ( INCY )  Down 1.8% Since Last Earnings Report?",
            "url": "https://www.zacks.com/stock/news/2191659/why-is-incyte-incy-down-18-since-last-earnings-report",
            "time_published": "20231130T163101",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Incyte (INCY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default301.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976671"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.124792,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.109789",
                    "ticker_sentiment_score": "0.041379",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INCY",
                    "relevance_score": "0.450266",
                    "ticker_sentiment_score": "0.147121",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk Sues Florida Compounding Pharmacies Over Impurities In Products Claiming To Contain Wegovy Ingredient - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/36020513/novo-nordisk-sues-florida-compounding-pharmacies-over-impurities-in-products-claiming-to-contain-",
            "time_published": "20231130T160946",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO has reportedly taken legal action against Florida compounding pharmacies, suing one and refiling a lawsuit against another, as it discovered impurities in their products claiming to contain the active ingredient, semaglutide, for its popular weight-loss drug Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/30/wegovy-company.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.106986,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.227007",
                    "ticker_sentiment_score": "0.081856",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.529185",
                    "ticker_sentiment_score": "0.290204",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights AbbVie, J&J, Eli Lilly, Pfizer",
            "url": "https://www.zacks.com/stock/news/2191547/the-zacks-analyst-blog-highlights-abbvie-jj-eli-lilly-pfizer",
            "time_published": "20231130T150800",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "AbbVie, J&J, Eli Lilly, Pfizer are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/1612.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.289723,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.236036",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.25168",
                    "ticker_sentiment_score": "0.248174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RXDX",
                    "relevance_score": "0.042647",
                    "ticker_sentiment_score": "0.013655",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.210823",
                    "ticker_sentiment_score": "0.152176",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.085173",
                    "ticker_sentiment_score": "0.093572",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly's Weight-Management Drug Outperformed Ozempic. Is It Time to Buy?",
            "url": "https://www.fool.com/investing/2023/11/30/eli-lillys-weight-management-drug-outperformed-oze/",
            "time_published": "20231130T102600",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Electronic health records say tirzepatide, the active ingredient in Mounjaro and Zepbound, is better at reducing weight than semaglutide, the active ingredient in Ozempic and Wegovy.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756222%2Fwall-street-analyst-with-laptop-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.202678,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.207697",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.069094",
                    "ticker_sentiment_score": "0.052515",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alexandria  ( ARE ) , Eli Lilly to Expand Gateway Labs to San Diego",
            "url": "https://www.zacks.com/stock/news/2190957/alexandria-are-eli-lilly-to-expand-gateway-labs-to-san-diego",
            "time_published": "20231129T152800",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "The expansion of Gateway Labs to San Diego reaffirms the strength and depth of the partnership between Alexandria (ARE) and Eli Lilly.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/88/400.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.368136,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.526867",
                    "ticker_sentiment_score": "0.503431",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "STAG",
                    "relevance_score": "0.155118",
                    "ticker_sentiment_score": "0.155557",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ARE",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.206109",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "IRM",
                    "relevance_score": "0.103778",
                    "ticker_sentiment_score": "0.135562",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Counterfeit Ozempic Raises Alarms - Lebanon Reports Hypoglycemia Cases - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/36001483/counterfeit-ozempic-raises-alarms-lebanon-reports-hypoglycemia-cases",
            "time_published": "20231129T151701",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Lebanese health officials have reported eleven cases of severe hypoglycemia linked to suspected fake versions of Novo Nordisk A/S's NVO diabetes medication Ozempic. Hypoglycemia is a condition in which the blood sugar ( glucose ) level is lower than the standard range.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/29/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.124498,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.303175",
                    "ticker_sentiment_score": "-0.118556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.56415",
                    "ticker_sentiment_score": "-0.284951",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "4 Large Drug Stocks to Watch as IBD Market Gains Traction",
            "url": "https://www.zacks.com/stock/news/2190845/4-large-drug-stocks-to-watch-as-ibd-market-gains-traction",
            "time_published": "20231129T143900",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "As demand for novel IBD treatments rises, investment in this dynamic sector could be rewarding. Some of the key players in the market are AbbVie (ABBV), J&J (JNJ), Lilly (LLY) and Pfizer (PFE).",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/62/5473.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.303098,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.223659",
                    "ticker_sentiment_score": "0.267409",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.223659",
                    "ticker_sentiment_score": "0.259888",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "RXDX",
                    "relevance_score": "0.04531",
                    "ticker_sentiment_score": "0.013756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.179788",
                    "ticker_sentiment_score": "0.167822",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.090474",
                    "ticker_sentiment_score": "0.082091",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Invesco Large Cap Growth ETF  ( PWB )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2190657/is-invesco-large-cap-growth-etf-pwb-a-strong-etf-right-now",
            "time_published": "20231129T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default359.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999965"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.351163,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.055094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.055094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.11894",
                    "ticker_sentiment_score": "0.055094",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.291644",
                    "ticker_sentiment_score": "0.388958",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Receives Some Very Bad News: Is It Time to Sell Novo Nordisk Stock?",
            "url": "https://www.fool.com/investing/2023/11/29/ozempic-bad-news-time-to-sell-novo-nordisk-stock/",
            "time_published": "20231129T105000",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Real-world data showed some real-world advantages for Ozempic's top rival.",
            "banner_image": "https://g.foolcdn.com/editorial/images/756269/ozempic.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.151467,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.254973",
                    "ticker_sentiment_score": "0.165545",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.430716",
                    "ticker_sentiment_score": "0.151452",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly's Options: A Look at What the Big Money is Thinking - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35987423/eli-lillys-options-a-look-at-what-the-big-money-is-thinking",
            "time_published": "20231128T193049",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.036029,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.755086",
                    "ticker_sentiment_score": "0.122038",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.092569",
                    "ticker_sentiment_score": "-0.13364",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Large Drug Stocks That Have Outperformed Industry YTD",
            "url": "https://www.zacks.com/stock/news/2190256/3-large-drug-stocks-that-have-outperformed-industry-ytd",
            "time_published": "20231128T140800",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY), Novo Nordisk (NVO) and Novartis (NVS) have outperformed the industry this year.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ab/2180.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.875462"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.451494"
                }
            ],
            "overall_sentiment_score": 0.159874,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.351184",
                    "ticker_sentiment_score": "0.138445",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.224072",
                    "ticker_sentiment_score": "0.184503",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "KDNY",
                    "relevance_score": "0.045396",
                    "ticker_sentiment_score": "0.096936",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Announces Plans to Open its First-ever Gateway Labs Site in San Diego",
            "url": "https://www.prnewswire.com/news-releases/lilly-announces-plans-to-open-its-first-ever-gateway-labs-site-in-san-diego-301998388.html",
            "time_published": "20231128T130000",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "Scheduled to open in the first half of 2024, Lilly's new Gateway Labs location, in partnership with Alexandria Real Estate Equities, will feature a world-class, state-of-the-art lab facility to support early-stage scientific entrepreneurs and companies",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.353835,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.128478",
                    "ticker_sentiment_score": "0.208581",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.706839",
                    "ticker_sentiment_score": "0.533865",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.064449",
                    "ticker_sentiment_score": "0.170257",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego - Alexandria Real Estate  ( NYSE:ARE ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/pressreleases/23/11/n35976480/alexandria-real-estate-equities-inc-announces-exclusive-partnership-with-lilly-to-expand-lilly-gat",
            "time_published": "20231128T130000",
            "authors": [
                "PRNewswire"
            ],
            "summary": "Alexandria and Lilly, which began their strategic relationship in 2008, are collaborating to support and accelerate the development of promising early-stage companies in the growing San Diego life science ecosystem PASADENA, Calif., Nov. 28, 2023 /PRNewswire/ -- Alexandria Real Estate Equities, ...",
            "banner_image": "https://cdnwp-s3.benzinga.com/wp-content/uploads/2023/11/17101453/Nada-Austin-Cityfund-2.jpg?optimize=medium&dpr=2&auto=webp&width=3840",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.459462"
                }
            ],
            "overall_sentiment_score": 0.401005,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.157278",
                    "ticker_sentiment_score": "0.266072",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.500072",
                    "ticker_sentiment_score": "0.540364",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AGTEF",
                    "relevance_score": "0.094762",
                    "ticker_sentiment_score": "0.235006",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San Diego",
            "url": "https://www.prnewswire.com/news-releases/alexandria-real-estate-equities-inc-announces-exclusive-partnership-with-lilly-to-expand-lilly-gateway-labs-to-san-diego-301998605.html",
            "time_published": "20231128T130000",
            "authors": [
                "Alexandria Real Estate Equities",
                "Inc."
            ],
            "summary": "Alexandria Real Estate Equities, Inc. Announces Exclusive Partnership With Lilly to Expand Lilly Gateway Labs to San ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/1930628/Alexandria_Real_Estate_Equities_Logo_v1.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                }
            ],
            "overall_sentiment_score": 0.369382,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ARE",
                    "relevance_score": "0.137514",
                    "ticker_sentiment_score": "0.249122",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.467081",
                    "ticker_sentiment_score": "0.4391",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AGTEF",
                    "relevance_score": "0.082772",
                    "ticker_sentiment_score": "0.231883",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly's Blockbuster Mounjaro Shows Larger, Faster Weight Loss Than Novo Nordisk's Ozempic In Real World Study - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35973774/eli-lillys-blockbuster-mounjaro-shows-larger-faster-weight-loss-than-novo-nordisks-ozempic-in-rea",
            "time_published": "20231128T113427",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "A recent extensive analysis by Truveta Research has revealed that Eli Lilly And Co's LLY blockbuster diabetes drug Mounjaro ( tirzepatide ) , proves more effective for weight loss in overweight or obese adults compared to Novo Nordisk A/S's NVO Ozempic ( semaglutide ) .",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/28/lly_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": -0.102295,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.128437",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.128437",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the Invesco Pharmaceuticals ETF  ( PJP ) ?",
            "url": "https://www.zacks.com/stock/news/2190100/should-you-invest-in-the-invesco-pharmaceuticals-etf-pjp",
            "time_published": "20231128T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default176.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.184982,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.063182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.063182",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.256314",
                    "ticker_sentiment_score": "0.095388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.129866",
                    "ticker_sentiment_score": "0.063182",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Flexible Pricing Approach: Push for Broader Access, Innovative Payments - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35957345/novo-nordisks-flexible-pricing-approach-push-for-broader-access-innovative-payments",
            "time_published": "20231127T160423",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Novo Nordisk A/S NVO is reportedly discussing with healthcare systems to introduce innovative pricing arrangements for its popular weight loss drug, Wegovy.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/27/nvo_1.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.174765,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.238133",
                    "ticker_sentiment_score": "-0.125864",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.711131",
                    "ticker_sentiment_score": "0.324001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "3 Top Stocks That'll Make Smart Investors Rich",
            "url": "https://www.fool.com/investing/2023/11/27/3-top-stocks-thatll-make-smart-investors-rich/",
            "time_published": "20231127T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Long-term investing is one possible path to riches.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755924%2Fhappy-person-at-laptop-success-winning-fists-up-victory-yes.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.332593,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.219312",
                    "ticker_sentiment_score": "0.229806",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.323785",
                    "ticker_sentiment_score": "0.261844",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The Zacks Analyst Blog Highlights Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce",
            "url": "https://www.zacks.com/stock/news/2189455/the-zacks-analyst-blog-highlights-eli-lilly-accenture-tjx-novo-nordisk-and-salesforce",
            "time_published": "20231127T091300",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Eli Lilly, Accenture, TJX, Novo Nordisk and Salesforce are included in this Analyst Blog.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.275414,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "CURN",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.113551",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.137278",
                    "ticker_sentiment_score": "0.036033",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "G",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.396052",
                    "ticker_sentiment_score": "0.12645",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.068896",
                    "ticker_sentiment_score": "-0.105477",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.33446",
                    "ticker_sentiment_score": "0.370877",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Is Pfizer Stock a Buy Ahead of This Highly Anticipated Weight Loss Readout?",
            "url": "https://www.fool.com/investing/2023/11/26/is-pfizer-stock-a-buy-ahead-of-this-highly-anticip/",
            "time_published": "20231126T190000",
            "authors": [
                "George Budwell"
            ],
            "summary": "An upcoming mid-stage readout may not spark a trend reversal in the big pharma's shares.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F756106%2Ftime-to-buy.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.036021,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.199037",
                    "ticker_sentiment_score": "-0.016043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.13347",
                    "ticker_sentiment_score": "0.041475",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.325637",
                    "ticker_sentiment_score": "-0.112992",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Fantastic Dividend Stocks to Buy Sooner Rather Than Later",
            "url": "https://www.fool.com/investing/2023/11/26/3-fantastic-dividend-stocks-to-buy-sooner-rather-t/",
            "time_published": "20231126T115500",
            "authors": [
                "and Prosper Junior Bakiny",
                "Keith Speights",
                "David Jagielski"
            ],
            "summary": "There's no time like the present to buy these stocks.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755957/retired-woman-investing-laptop-401k-ira.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995015"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.658903"
                }
            ],
            "overall_sentiment_score": 0.300996,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.393634",
                    "ticker_sentiment_score": "0.433055",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.393634",
                    "ticker_sentiment_score": "0.213478",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.225321",
                    "ticker_sentiment_score": "0.13405",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Five S&P 500 Stocks Near Buy Points",
            "url": "https://www.investors.com/news/sp-500-google-leads-5-stocks-near-buy-points/",
            "time_published": "20231125T133300",
            "authors": [
                "Investor's Business Daily",
                "JED GRAHAM"
            ],
            "summary": "S&P 500: Google Leads Five Stocks Near Buy Points Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/01/Stock-googleworkers-01-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999966"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.095782,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.091393",
                    "ticker_sentiment_score": "0.091357",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HLT",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.030524",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.12165",
                    "ticker_sentiment_score": "0.107881",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "V",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.127018",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EXPE",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.15173",
                    "ticker_sentiment_score": "0.076155",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.061003",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.058275",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.15173",
                    "ticker_sentiment_score": "0.072302",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Could Ozempic Harm These 3 Medical Device Stocks?",
            "url": "https://www.fool.com/investing/2023/11/25/could-ozempic-harm-these-3-medical-device-stocks/",
            "time_published": "20231125T115800",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The drug is on track to cause massive competitive shifts in the healthcare sector.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755826/investors-discuss-investment-at-table.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.043378,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.102231",
                    "ticker_sentiment_score": "0.086548",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EW",
                    "relevance_score": "0.152821",
                    "ticker_sentiment_score": "0.056489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.102231",
                    "ticker_sentiment_score": "-0.044851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSX",
                    "relevance_score": "0.152821",
                    "ticker_sentiment_score": "0.034841",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Salesforce.com, Pure Storage And The Nasdaq's November Hurdle: Investing Action Plan",
            "url": "https://www.investors.com/research/investing-action-plan/salesforce-com-pure-storage-and-nasdaqs-november-hurdle-investing-action-plan/",
            "time_published": "20231124T211500",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "Salesforce.com, Pure Storage And The Nasdaq's November Hurdle ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/11/Stock-TurkeyCarThanksgiving-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999186"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.1234,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "C",
                    "relevance_score": "0.025569",
                    "ticker_sentiment_score": "0.065952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.103421",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DG",
                    "relevance_score": "0.127321",
                    "ticker_sentiment_score": "-0.007338",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INTU",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.024686",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FL",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "-0.237539",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.061857",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HPQ",
                    "relevance_score": "0.025569",
                    "ticker_sentiment_score": "0.057721",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TITN",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.045899",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTAP",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.063061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PDD",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.163174",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PSTG",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.060241",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MA",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "-0.024983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "-0.025545",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DELL",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "0.045459",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "-0.025545",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIG",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "-0.006192",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "-0.024983",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.025569",
                    "ticker_sentiment_score": "0.207993",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.105698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ULTA",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.101116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DLTR",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "-0.006663",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BRK-A",
                    "relevance_score": "0.025569",
                    "ticker_sentiment_score": "0.044518",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KR",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.047945",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.025569",
                    "ticker_sentiment_score": "-0.005686",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WDAY",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.003993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LZB",
                    "relevance_score": "0.127321",
                    "ticker_sentiment_score": "0.096582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNPS",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.06354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.105698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPLK",
                    "relevance_score": "0.102013",
                    "ticker_sentiment_score": "0.11119",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HPE",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.06354",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MAR",
                    "relevance_score": "0.076602",
                    "ticker_sentiment_score": "-0.025545",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRVL",
                    "relevance_score": "0.051111",
                    "ticker_sentiment_score": "0.058563",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Top Stock Reports for Eli Lilly, Accenture & The TJX Companies",
            "url": "https://www.zacks.com/research-daily/2188872/top-stock-reports-for-eli-lilly-accenture-the-tjx-companies",
            "time_published": "20231124T174700",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "Today's Research Daily features new research reports on 16 major stocks, including Eli Lilly and Company (LLY), Accenture plc (ACN) and The TJX Companies, Inc. (TJX).",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default200.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.335543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.140756",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CURN",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "-0.11299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INFY",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "-0.11299",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.277958",
                    "ticker_sentiment_score": "0.282967",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.187463",
                    "ticker_sentiment_score": "0.458965",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "G",
                    "relevance_score": "0.09439",
                    "ticker_sentiment_score": "-0.11299",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo Nordisk  ( NVO )  to Expand Manufacturing Site in France",
            "url": "https://www.zacks.com/stock/news/2189006/novo-nordisk-nvo-to-expand-manufacturing-site-in-france",
            "time_published": "20231124T143000",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Novo Nordisk (NVO) announces that it is initiating plans to expand its existing manufacturing facility in Chartres, France, for the current and future product portfolio within serious chronic diseases.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/de/2471.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.198265,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.307603",
                    "ticker_sentiment_score": "0.290043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.307603",
                    "ticker_sentiment_score": "0.104707",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.531716",
                    "ticker_sentiment_score": "0.191818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.208017",
                    "ticker_sentiment_score": "0.087543",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: NVO & LLY to Expand Manufacturing Capacity in Europe, & More",
            "url": "https://www.zacks.com/stock/news/2188971/pharma-stock-roundup-nvo-lly-to-expand-manufacturing-capacity-in-europe-more",
            "time_published": "20231124T141500",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Eli Lilly (LLY) plans to build a $2.5 billion manufacturing plant in Germany. Novo Nordisk (NVO) plans to invest $2.3 billion to expand an existing production site in France.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": 0.177856,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.390613",
                    "ticker_sentiment_score": "0.148198",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.390613",
                    "ticker_sentiment_score": "0.206145",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.058188",
                    "ticker_sentiment_score": "-0.119988",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "$3,000 Invested in These 3 Top Stocks Could Make You Rich in 10 Years",
            "url": "https://www.fool.com/investing/2023/11/23/3000-invested-in-these-3-top-stocks-could-make-you/",
            "time_published": "20231123T142600",
            "authors": [
                "James Brumley"
            ],
            "summary": "Plug into a trio of megatrends with these three particular tickers.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755660/rich-millionaire-billionaire-raining-money.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.245987,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.145952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LTRCF",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.259376",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.040899",
                    "ticker_sentiment_score": "0.145952",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.081691",
                    "ticker_sentiment_score": "0.163486",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.162528",
                    "ticker_sentiment_score": "0.027408",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.282297",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Will Eli Lilly Be Worth More Than Tesla by 2027?",
            "url": "https://www.fool.com/investing/2023/11/23/will-eli-lilly-be-worth-more-than-tesla-by-2027/",
            "time_published": "20231123T140500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It's a lot more likely than it sounds.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755823/woman-stock-broker-investor-tracking-stocks.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990786"
                }
            ],
            "overall_sentiment_score": 0.292276,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.413049",
                    "ticker_sentiment_score": "0.371741",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.282777",
                    "ticker_sentiment_score": "0.316733",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly  ( LLY )  Stock Outperforms Industry YTD: Here's Why",
            "url": "https://www.zacks.com/stock/news/2188291/eli-lilly-lly-stock-outperforms-industry-ytd-heres-why",
            "time_published": "20231123T131600",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) is making rapid pipeline progress in areas like obesity, diabetes and Alzheimer's. Mounjaro and Zepbound are expected to be key top-line drivers for Lilly.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99237"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.200803,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.547615",
                    "ticker_sentiment_score": "0.27041",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.227432",
                    "ticker_sentiment_score": "0.150556",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HARP",
                    "relevance_score": "0.271274",
                    "ticker_sentiment_score": "0.113804",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.182851",
                    "ticker_sentiment_score": "0.04394",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "$1000 Invested In Eli Lilly 10 Years Ago Would Be Worth This Much Today - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/11/35916026/1000-invested-in-eli-lilly-10-years-ago-would-be-worth-this-much-today",
            "time_published": "20231122T140021",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly LLY has outperformed the market over the past 10 years by 18.31% on an annualized basis producing an average annual return of 27.97%. Currently, Eli Lilly has a market capitalization of $565.31 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.375984",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "New ETF invested in Ozempic maker and exposed to other obesity drugs falls in first day of trade",
            "url": "https://www.marketwatch.com/story/new-etf-invested-in-ozempic-maker-and-exposed-to-other-obesity-drugs-falls-in-first-day-of-trade-a489a9b0",
            "time_published": "20231122T130100",
            "authors": [
                "Christine Idzelis"
            ],
            "summary": "The new Tema Cardiovascular and Metabolic ETF fell in its first day of trade. It is exposed to weight-loss drugs including Ozempic.",
            "banner_image": "https://images.mktw.net/im-75709773/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.650727"
                }
            ],
            "overall_sentiment_score": 0.297411,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.690822",
                    "ticker_sentiment_score": "0.056772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.04038",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Best Stocks to Invest $5,000 in Right Now",
            "url": "https://www.fool.com/investing/2023/11/22/the-best-stocks-to-invest-5000-in-right-now/",
            "time_published": "20231122T130000",
            "authors": [
                "Joe Tenebruso"
            ],
            "summary": "Here's how to safeguard your money and grow richer.",
            "banner_image": "https://g.foolcdn.com/editorial/images/755596/investor-gettyimages-1150017950.jpg",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.495866"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.31959,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.070935",
                    "ticker_sentiment_score": "-0.053085",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.14131",
                    "ticker_sentiment_score": "0.01183",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.343755",
                    "ticker_sentiment_score": "0.380224",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the Health Care Select Sector SPDR ETF  ( XLV ) ?",
            "url": "https://www.zacks.com/stock/news/2187631/should-you-invest-in-the-health-care-select-sector-spdr-etf-xlv",
            "time_published": "20231122T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default50.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.301216,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.060142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.127366",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.089049",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.060142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.060142",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Alzheimer's Disease Vaccines: Promising Developments, Renewed Enthusiasm From Biogen, Eli Lilly And Others - Biogen  ( NASDAQ:BIIB ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35901610/alzheimers-disease-vaccines-promising-developments-renewed-enthusiasm-from-biogen-eli-lilly-and-o",
            "time_published": "20231121T201625",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Recent advancements in Alzheimer's disease treatments targeting the removal of toxic proteins ( white matter ) from the brain have sparked a renewed interest in developing vaccines to combat this memory-robbing disease.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/21/aapharma_5.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.087042,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "ACIU",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.303386",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "-0.07556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.303386",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VAXX",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "0.303386",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "-0.048396",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "-0.07556",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "ABBV vs. LLY: Which Stock Should Value Investors Buy Now?",
            "url": "https://www.zacks.com/stock/news/2187390/abbv-vs-lly-which-stock-should-value-investors-buy-now",
            "time_published": "20231121T164006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "ABBV vs. LLY: Which Stock Is the Better Value Option?",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default172.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.48939,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.69701",
                    "ticker_sentiment_score": "0.58128",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.802099",
                    "ticker_sentiment_score": "0.607342",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Can Weight-Loss Drug Ozempic Tip The Scales For Tema's New Healthcare ETF? - Harvest Oil & Gas  ( OTC:HRST ) , Tema Oncology ETF  ( NASDAQ:CANC ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35894597/can-weight-loss-drug-ozempic-tip-the-scales-for-temas-new-healthcare-etf",
            "time_published": "20231121T135513",
            "authors": [
                "Neil Dennis"
            ],
            "summary": "Tema, the exchange-traded fund platform, has launched a healthcare ETF focused on companies that research and treat cardiovascular disease and conditions associated with obesity and diabetes, including Novo Nordisk, maker of the blockbuster diet drug Ozempic.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/weight-loss-shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967321"
                }
            ],
            "overall_sentiment_score": 0.189157,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.067322",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MDGL",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "-0.059766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MASI",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "-0.059766",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.189013",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.177802",
                    "ticker_sentiment_score": "0.050661",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should Invesco Large Cap Growth ETF  ( PWB )  Be on Your Investing Radar?",
            "url": "https://www.zacks.com/stock/news/2187018/should-invesco-large-cap-growth-etf-pwb-be-on-your-investing-radar",
            "time_published": "20231121T112007",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Style Box ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default333.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.289113,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.061251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.061251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COST",
                    "relevance_score": "0.121343",
                    "ticker_sentiment_score": "0.061251",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.297301",
                    "ticker_sentiment_score": "0.269385",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Should You Invest in the iShares U.S. Healthcare ETF  ( IYH ) ?",
            "url": "https://www.zacks.com/stock/news/2187024/should-you-invest-in-the-ishares-us-healthcare-etf-iyh",
            "time_published": "20231121T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default135.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.251101,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.088211",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.070304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.070304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.070304",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ignore Eli Lilly. These 2 Stocks Are Better Buys Right Now",
            "url": "https://www.fool.com/investing/2023/11/21/ignore-eli-lilly-these-2-stocks-are-better-buys/",
            "time_published": "20231121T103000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "Investors have favored an exciting billion-dollar opportunity at Eli Lilly.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755638%2Fgettyimages-1320686310.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999822"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.245009,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.3796",
                    "ticker_sentiment_score": "0.458528",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.428632",
                    "ticker_sentiment_score": "0.15879",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.47574",
                    "ticker_sentiment_score": "0.237818",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Stock Of The Day Lilly Nears A Record - Again - As It Enters The Obesity Arena",
            "url": "https://www.investors.com/research/ibd-stock-of-the-day/eli-lilly-stock-is-nearing-a-record-again-as-it-enters-the-weight-loss-drugs-arena/",
            "time_published": "20231120T194100",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Stock Of The Day Lilly Nears A Record - Again - As It Enters The ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/SOTD-11-20-23LLY.png",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.365926"
                }
            ],
            "overall_sentiment_score": 0.215926,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.677342",
                    "ticker_sentiment_score": "0.342773",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.106211",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly  ( LLY )  to Build $2.5B Plant to Meet Increased Drug Demand",
            "url": "https://www.zacks.com/stock/news/2186768/lilly-lly-to-build-25b-plant-to-meet-increased-drug-demand",
            "time_published": "20231120T163100",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Through this expansion, Eli Lilly (LLY) intends to expand its global manufacturing footprint to support the rising demand for its diabetes and obesity portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.206281,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.554365",
                    "ticker_sentiment_score": "0.435138",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.388879",
                    "ticker_sentiment_score": "0.184577",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.328236",
                    "ticker_sentiment_score": "0.044137",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.265378",
                    "ticker_sentiment_score": "0.198716",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Investors Heavily Search Eli Lilly and Company  ( LLY ) : Here is What You Need to Know",
            "url": "https://www.zacks.com/stock/news/2186534/investors-heavily-search-eli-lilly-and-company-lly-here-is-what-you-need-to-know",
            "time_published": "20231120T140011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default340.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.223965,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.528798",
                    "ticker_sentiment_score": "0.14785",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "A Look Into Eli Lilly Inc's Price Over Earnings - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/11/35872137/a-look-into-eli-lilly-incs-price-over-earnings",
            "time_published": "20231120T134517",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "In the current session, the stock is trading at $593.00, after a 0.22% increase. Over the past month, Eli Lilly Inc. LLY stock increased by 0.10%, and in the past year, by 64.32%.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.413559"
                }
            ],
            "overall_sentiment_score": 0.221002,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.443626",
                    "ticker_sentiment_score": "0.240819",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Billionaires Bullish on Big Tech: ETFs in Focus",
            "url": "https://www.zacks.com/stock/news/2186501/billionaires-bullish-on-big-tech-etfs-in-focus",
            "time_published": "20231120T134000",
            "authors": [
                "Sanghamitra Saha"
            ],
            "summary": "The latest 13-F filings of billionaires indicate that most are still bullish on big techs.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/d9/21892.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999997"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.281065,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.143131",
                    "ticker_sentiment_score": "0.179641",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.281692",
                    "ticker_sentiment_score": "0.217215",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.095707",
                    "ticker_sentiment_score": "0.129097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.143131",
                    "ticker_sentiment_score": "0.130822",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.236281",
                    "ticker_sentiment_score": "0.162799",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.190043",
                    "ticker_sentiment_score": "0.205221",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.04794",
                    "ticker_sentiment_score": "0.11985",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.095707",
                    "ticker_sentiment_score": "0.099802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPNG",
                    "relevance_score": "0.095707",
                    "ticker_sentiment_score": "0.099802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.236281",
                    "ticker_sentiment_score": "0.273944",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TCKRF",
                    "relevance_score": "0.04794",
                    "ticker_sentiment_score": "0.093956",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Just Got One Step Closer to Dethroning Ozempic. Time to Buy the Stock?",
            "url": "https://www.fool.com/investing/2023/11/19/eli-lilly-just-got-one-step-closer-to-dethroning-o/",
            "time_published": "20231119T110500",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Eli Lilly just received FDA approval for its obesity medication Zepbound, the sister treatment to its blockbuster drug Mounjaro.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F755134%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.210864,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BCS",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.130891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.130891",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.132733",
                    "ticker_sentiment_score": "0.064572",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.522486",
                    "ticker_sentiment_score": "0.289301",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNY",
                    "relevance_score": "0.033328",
                    "ticker_sentiment_score": "0.105236",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Goldman Sachs expects below-average returns for the next 2 years. It shares 3 strategies to beat the market and 23 stock picks across them.",
            "url": "https://www.businessinsider.com/goldman-sachs-2024-top-stocks-to-buy-beat-market-2023-11",
            "time_published": "20231118T093300",
            "authors": [
                "Laila Maidan"
            ],
            "summary": "Goldman Sachs: Buy These 23 Stocks to Beat the Market in 2024 - Business Insider ...",
            "banner_image": "https://i.insider.com/6557d41336d588dc55d2b002?width=1200&format=jpeg",
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.209774,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "ALK",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.080374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ENPH",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.176304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MPC",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.176304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TTC",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.080374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHW",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CROX",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.080374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMT",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "EQT",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.176304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ICE",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "-0.026199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DAL",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.080374",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ELV",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROL",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TFC",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AWK",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ORLY",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.113417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALB",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.176304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.060388",
                    "ticker_sentiment_score": "0.155022",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.176304",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JBT",
                    "relevance_score": "0.120431",
                    "ticker_sentiment_score": "0.080374",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Options Trading: A Deep Dive into Market Sentiment - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35852293/eli-lilly-options-trading-a-deep-dive-into-market-sentiment",
            "time_published": "20231117T164552",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Whales with a lot of money to spend have taken a noticeably bearish stance on Eli Lilly. Looking at options history for Eli Lilly LLY we detected 16 trades. If we consider the specifics of each trade, it is accurate to state that 43% of the investors opened trades with bullish expectations and ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.045373,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.718485",
                    "ticker_sentiment_score": "-0.081152",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "How Danaher's new acquisition will boost earnings for the life sciences firm",
            "url": "https://www.cnbc.com/2023/11/17/how-danahers-new-acquisition-will-boost-earnings.html",
            "time_published": "20231117T161908",
            "authors": [
                "Jeff Marks"
            ],
            "summary": "The Investing Club holds its Morning Meeting every weekday at 10:20 a.m. ET.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107335733-17002352821700235277-32066339062-1080pnbcnews.jpg?v=1700235282&w=600&h=300&vtcrop=y",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.938793"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.178654,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.358152",
                    "ticker_sentiment_score": "0.190117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ABCM",
                    "relevance_score": "0.183895",
                    "ticker_sentiment_score": "0.113534",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CTRA",
                    "relevance_score": "0.272788",
                    "ticker_sentiment_score": "0.154306",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DHR",
                    "relevance_score": "0.358152",
                    "ticker_sentiment_score": "0.190117",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The War In Alzheimer's Treatment Is Just Beginning",
            "url": "https://www.investors.com/news/technology/biotech-stocks-the-war-in-alzheimers-treatment-is-just-beginning-why-there-is-still-hope/",
            "time_published": "20231117T131500",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "Biotech Stocks: The Race For An Alzheimer's Cure Takes Off Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/A1jump2c-112023-1024x384.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                }
            ],
            "overall_sentiment_score": 0.123012,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "VAXX",
                    "relevance_score": "0.067871",
                    "ticker_sentiment_score": "-0.096986",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "INMB",
                    "relevance_score": "0.033966",
                    "ticker_sentiment_score": "-0.089096",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.067871",
                    "ticker_sentiment_score": "0.189791",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NHPEF",
                    "relevance_score": "0.016987",
                    "ticker_sentiment_score": "-0.009199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PRTA",
                    "relevance_score": "0.05093",
                    "ticker_sentiment_score": "0.057996",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABOS",
                    "relevance_score": "0.033966",
                    "ticker_sentiment_score": "0.068935",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.05093",
                    "ticker_sentiment_score": "-0.09242",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.135252",
                    "ticker_sentiment_score": "0.103934",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.033966",
                    "ticker_sentiment_score": "-0.088133",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.21806",
                    "ticker_sentiment_score": "0.140978",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma Stock Roundup: FDA Okays AZN's Capivasertib & MRK's Keytruda Expanded Use",
            "url": "https://www.zacks.com/stock/news/2185842/pharma-stock-roundup-fda-okays-azns-capivasertib-mrks-keytruda-expanded-use",
            "time_published": "20231117T131400",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "FDA approves AstraZeneca's (AZN) new breast cancer drug, Truqap, and the expanded use of Merck's (MRK) Keytruda in a gastric cancer indication ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/cf/2377.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.036697,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "0.002274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "-0.068544",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.224903",
                    "ticker_sentiment_score": "-0.061435",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.113597",
                    "ticker_sentiment_score": "0.002274",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly to expand injectable manufacturing capacity with planned $2.5 billion site in Germany",
            "url": "https://www.prnewswire.com/news-releases/lilly-to-expand-injectable-manufacturing-capacity-with-planned-2-5-billion-site-in-germany-301990884.html",
            "time_published": "20231117T130000",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "Company also commits to investing up to $100 million in German early-stage life sciences ecosystem INDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced plans to construct a new $2.5 billion high-tech manufacturing site in Alzey, Rhineland-Palatinate, ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999864"
                }
            ],
            "overall_sentiment_score": 0.344147,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.445419",
                    "ticker_sentiment_score": "0.381368",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "13F Rundown: Tepper, Buffett, Druckenmiller",
            "url": "https://www.zacks.com/commentary/2185646/13f-rundown-tepper-buffett-druckenmiller",
            "time_published": "20231117T130000",
            "authors": [
                "Andrew Rocco"
            ],
            "summary": "Stock Strategist Andrew Rocco divulges valuable insights from the world's best and brightest investors.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/1d/26991.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.918141"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": 0.234041,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BABA",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.196542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.2872",
                    "ticker_sentiment_score": "0.208936",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.196542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.354572",
                    "ticker_sentiment_score": "0.244913",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.206432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "-0.052481",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.206432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.206432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.074495",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CPNG",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.074495",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.146025",
                    "ticker_sentiment_score": "0.196542",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TCKRF",
                    "relevance_score": "0.073321",
                    "ticker_sentiment_score": "0.058869",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Extends Tender Offer to Acquire POINT Biopharma to Dec. 1, 2023",
            "url": "https://www.prnewswire.com/news-releases/lilly-extends-tender-offer-to-acquire-point-biopharma-to-dec-1-2023-301991468.html",
            "time_published": "20231117T114500",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "INDIANAPOLIS, Nov. 17, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ( \"Shares\" ) of common stock of POINT Biopharma Global Inc. ( NASDAQ: PNT ) , for a purchase ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.999973"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.270864,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.445848",
                    "ticker_sentiment_score": "0.337712",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.033703",
                    "ticker_sentiment_score": "0.165279",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CMSQF",
                    "relevance_score": "0.033703",
                    "ticker_sentiment_score": "0.183624",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.067347",
                    "ticker_sentiment_score": "0.064405",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is Goldman Sachs Equal Weight U.S. Large Cap Equity ETF  ( GSEW )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2185779/is-goldman-sachs-equal-weight-us-large-cap-equity-etf-gsew-a-strong-etf-right-now",
            "time_published": "20231117T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default213.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.99999"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.246215,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.171282",
                    "ticker_sentiment_score": "0.093832",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.050967",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TPL",
                    "relevance_score": "0.114682",
                    "ticker_sentiment_score": "0.050967",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharmaceutical Giant Eli Lilly Plans Expansion In Germany, Eyes Diabetes Drug Production: Report - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35833897/pharmaceutical-giant-eli-lilly-plans-expansion-in-germany-eyes-diabetes-drug-production-report",
            "time_published": "20231116T195610",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co LLY reportedly intends to construct a production plant in western Germany with an estimated investment of €2 billion ( $2.17 billion ) , marking an inaugural substantial production facility in Germany and responding to the increasing pressure to localize critical healthcare ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/16/lly_2.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.061366,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.588876",
                    "ticker_sentiment_score": "-0.031488",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.318897",
                    "ticker_sentiment_score": "0.161857",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "10 'better values' in the stock market, selected for the next two years",
            "url": "https://www.marketwatch.com/story/10-better-values-in-the-stock-market-selected-for-the-next-two-years-5b9bc809",
            "time_published": "20231116T174900",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "William Blair's list of favored stocks for the next 24 months includes Five Below, Chewy and Allstate.",
            "banner_image": "https://images.mktw.net/im-33766063/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.955357"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99992"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.219504,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DT",
                    "relevance_score": "0.096932",
                    "ticker_sentiment_score": "0.076614",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NFLX",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.001002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.001002",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FIVE",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.405966",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "HOLX",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.090227",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FI",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.127165",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.005044",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHWY",
                    "relevance_score": "0.096932",
                    "ticker_sentiment_score": "0.047679",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.005044",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FUSN",
                    "relevance_score": "0.096932",
                    "ticker_sentiment_score": "0.02274",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOVT",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.024203",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ALGN",
                    "relevance_score": "0.06471",
                    "ticker_sentiment_score": "0.276794",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Better Growth Stock: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2023/11/16/better-growth-stock-novo-nordisk-vs-eli-lilly/",
            "time_published": "20231116T140000",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "These companies have been attracting plenty of attention lately.",
            "banner_image": "https://media.ycharts.com/charts/d9d350c38d32aecb1b4fde9093a7d584.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.87644"
                }
            ],
            "overall_sentiment_score": 0.337772,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.302553",
                    "ticker_sentiment_score": "0.331175",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.302553",
                    "ticker_sentiment_score": "0.137641",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "This Option Trade On Eli Lilly Stock Could Return 27% By Mid-January",
            "url": "https://www.investors.com/research/options/eli-lilly-stock-option-trade-benefits-from-decay/",
            "time_published": "20231116T133000",
            "authors": [
                "GAVIN McMASTER",
                "Investor's Business Daily"
            ],
            "summary": "Eli Lilly Stock Trade Benefits From Decay Of Option Prices Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/05/Stock-Lilly-01-Shutterstock.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": -0.002409,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.414559",
                    "ticker_sentiment_score": "0.076353",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "-0.182801",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "If You Invested $10,000 in Eli Lilly in 2013, This Is How Much You Would Have Today",
            "url": "https://www.fool.com/investing/2023/11/16/if-you-invested-10000-in-eli-lilly-in-2013-this-is/",
            "time_published": "20231116T115000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Is it too late to invest in Eli Lilly's stock?",
            "banner_image": "https://media.ycharts.com/charts/720f3a8e125c4a8e83a87ee57ad11aea.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.779048"
                }
            ],
            "overall_sentiment_score": 0.289943,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.506832",
                    "ticker_sentiment_score": "0.433512",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Should SPDR MSCI USA StrategicFactors ETF  ( QUS )  Be on Your Investing Radar?",
            "url": "https://www.zacks.com/stock/news/2185086/should-spdr-msci-usa-strategicfactors-etf-qus-be-on-your-investing-radar",
            "time_published": "20231116T112006",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Style Box ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default317.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.120182,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.124486",
                    "ticker_sentiment_score": "0.063095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.124486",
                    "ticker_sentiment_score": "0.063095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.124486",
                    "ticker_sentiment_score": "0.063095",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STT",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "0.048005",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Flopped While the Market Popped Today",
            "url": "https://www.fool.com/investing/2023/11/15/why-eli-lilly-stock-flopped-while-the-market-poppe/",
            "time_published": "20231115T230000",
            "authors": [
                "Eric Volkman"
            ],
            "summary": "The company is apparently gearing up to spend at least $1 billion on a production facility in Europe.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.099405,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.682689",
                    "ticker_sentiment_score": "0.171324",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Ozempic Shortage Crisis - Germany Weighs Export Restrictions on Novo Nordisk's Drug - Novo Nordisk  ( NYSE:NVO ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35804388/ozempic-shortage-crisis-germany-weighs-export-restrictions-on-novo-nordisks-drug",
            "time_published": "20231115T141744",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Germany's Federal Institute for Drugs and Medical Devices ( BfArM ) is reportedly contemplating a potential export prohibition on Novo Nordisk A/S's NVO popular diabetes medication, Ozempic, due to an ongoing scarcity.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/15/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.119026,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.241684",
                    "ticker_sentiment_score": "-0.237412",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.355588",
                    "ticker_sentiment_score": "0.09331",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is First Trust Capital Strength ETF  ( FTCS )  a Strong ETF Right Now?",
            "url": "https://www.zacks.com/stock/news/2184361/is-first-trust-capital-strength-etf-ftcs-a-strong-etf-right-now",
            "time_published": "20231115T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Smart Beta ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default201.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999953"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.319017,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.052174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CSCO",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.052174",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.052174",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Announces the Receipt of NRC Consent in Connection with its Proposed Acquisition of POINT Biopharma",
            "url": "https://www.prnewswire.com/news-releases/lilly-announces-the-receipt-of-nrc-consent-in-connection-with-its-proposed-acquisition-of-point-biopharma-301988209.html",
            "time_published": "20231114T213300",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "INDIANAPOLIS, Nov. 14, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced that the U.S.",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.999682"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.259816,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.436586",
                    "ticker_sentiment_score": "0.320293",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.03545",
                    "ticker_sentiment_score": "0.165986",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.07083",
                    "ticker_sentiment_score": "0.114979",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Employer coverage of GLP-1 drugs for weight loss lags far behind diabetes coverage, survey finds",
            "url": "https://www.marketwatch.com/story/employer-coverage-of-glp-1-drugs-for-weight-loss-lags-far-behind-diabetes-coverage-survey-finds-aa9f8936",
            "time_published": "20231114T203400",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Many employers hold off on coverage of Wegovy and similar drugs amid cost concerns and the prospect of cheaper options down the road ...",
            "banner_image": "https://images.mktw.net/im-886948/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.014386,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.247208",
                    "ticker_sentiment_score": "0.151982",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.125134",
                    "ticker_sentiment_score": "0.061688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.125134",
                    "ticker_sentiment_score": "0.251447",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Why These 8%+ Yielding Closed-End Funds Crush Low-Fee Index Funds",
            "url": "https://www.forbes.com/sites/michaelfoster/2023/11/14/why-these-8-yielding-closed-end-funds-crush-low-fee-index-funds/",
            "time_published": "20231114T131500",
            "authors": [
                "Michael Foster"
            ],
            "summary": "If you always wanted a free lunch but thought they don't exist, well, they kind of do, in the form of the Fidelity group of ZERO index funds, like the Fidelity ZERO Total Market Index Fund ( FZROX ) . After all, its 0% fees mean it should easily beat a closed-end fund ( CEF ) with a high expense ...",
            "banner_image": "https://imageio.forbes.com/specials-images/imageserve/65524d1af89e5ab719a48d38/0x0.jpg?format=jpg&height=900&width=1600&fit=bounds",
            "source": "Forbes",
            "category_within_source": "n/a",
            "source_domain": "www.forbes.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.503496"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.216148,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GAM-P-B",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.009817",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SLFPF",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "0.109532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAT",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SCHW",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "-0.122037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.042421",
                    "ticker_sentiment_score": "-0.122037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.084722",
                    "ticker_sentiment_score": "0.076958",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Is Planning to Dominate the Weight Loss Market and Make Billions. Here's Why It'll Keep Winning",
            "url": "https://www.fool.com/investing/2023/11/14/eli-lilly-is-planning-to-dominate-the-weight-loss/",
            "time_published": "20231114T124500",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "It's already taking actions to shore up its future position.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.232083,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.186738",
                    "ticker_sentiment_score": "0.149508",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.071643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.09402",
                    "ticker_sentiment_score": "0.176337",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Industry Outlook Highlights Eli Lilly, Novo Nordisk, J&J and AbbVie",
            "url": "https://www.zacks.com/stock/news/2183791/zacks-industry-outlook-highlights-eli-lilly-novo-nordisk-jj-and-abbvie",
            "time_published": "20231114T124200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Eli Lilly, Novo Nordisk, J&J and AbbVie are part of the Zacks Industry Outlook article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/ff/2922.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.996023"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.17517,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "-0.021479",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.140621",
                    "ticker_sentiment_score": "0.116722",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.030471",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.047092",
                    "ticker_sentiment_score": "0.060093",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.16375",
                    "ticker_sentiment_score": "0.056556",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.16375",
                    "ticker_sentiment_score": "0.136116",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "0.11584",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.023556",
                    "ticker_sentiment_score": "0.11584",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What Are Pfizer's Prospects In Obesity Pill Market? Analysts Say Optimism, Cautiousness Surround With Data Awaited Next Year - Pfizer  ( NYSE:PFE ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35757948/what-are-pfizers-prospects-in-obesity-pill-market-analysts-say-optimism-cautiousness-surround-wit",
            "time_published": "20231113T190421",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Pfizer Inc PFE is turning its focus to the weight loss drug market, aiming to capture a $10 billion segment with its experimental obesity pill, danuglipron.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/13/pfizer.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.186677,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.180461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.379051",
                    "ticker_sentiment_score": "0.180461",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.677342",
                    "ticker_sentiment_score": "-0.136366",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Is There Room for Improvement In Weight Loss Arena? Analysts Evaluate Novo Nordisk Data, Emphasize Opportunities for Eli Lilly - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/analyst-ratings/analyst-color/23/11/35757288/is-there-room-for-improvement-in-weight-loss-arena-analysts-evaluate-novo-nordisk-d",
            "time_published": "20231113T190010",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Eli Lilly And Co's LLY investigational RNA-directed drug lepodisiran lowered lipoprotein ( a ) levels in a Phase 1 study. Elevated levels of Lp ( a ) have been associated with a higher risk of heart disease, heart attack, and stroke.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/13/ozempic.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.13637,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.417995",
                    "ticker_sentiment_score": "0.291845",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.109455",
                    "ticker_sentiment_score": "0.14235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.21686",
                    "ticker_sentiment_score": "-0.090456",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Novo, Lilly Skid - But These Weight-Loss Results Are 'Hard To Ignore'",
            "url": "https://www.investors.com/news/technology/novo-nordisk-stock-can-weight-loss-drugs-prevent-diabetes/",
            "time_published": "20231113T162500",
            "authors": [
                "ALLISON GATLIN",
                "Investor's Business Daily"
            ],
            "summary": "Novo Nordisk Stock: Can Weight-Loss Drugs Prevent Diabetes? Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-Lab01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.995077"
                }
            ],
            "overall_sentiment_score": 0.03874,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "-0.057783",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.171906",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BAC",
                    "relevance_score": "0.120733",
                    "ticker_sentiment_score": "0.162739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MDT",
                    "relevance_score": "0.180236",
                    "ticker_sentiment_score": "0.26716",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DXCM",
                    "relevance_score": "0.238718",
                    "ticker_sentiment_score": "0.327328",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.295867",
                    "ticker_sentiment_score": "0.008872",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Stock Market Indexes Stumble As Moody's Cuts U.S. Rating; Boeing Soars On Deal News",
            "url": "https://www.investors.com/market-trend/stock-market-today/stock-market-indexes-stumble-as-moodys-cuts-us-rating/",
            "time_published": "20231113T155300",
            "authors": [
                "Investor's Business Daily",
                "RUSS BRITT"
            ],
            "summary": "Stock Market Indexes Stumble As Moody's Cuts U.S. Rating. Boeing ... Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2019/06/stock-boeing-777x-02-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.976913"
                }
            ],
            "overall_sentiment_score": 0.038317,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CPRT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.158305",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.102489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSEM",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "-0.230537",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.084639",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.040664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.057395",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.040664",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCO",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "-0.101647",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAMT",
                    "relevance_score": "0.093836",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.140348",
                    "ticker_sentiment_score": "0.047442",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.231773",
                    "ticker_sentiment_score": "0.007149",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "4 Large Drug Stocks Likely to Sail Through Industry Woes",
            "url": "https://www.zacks.com/commentary/2183148/4-large-drug-stocks-likely-to-sail-through-industry-woes",
            "time_published": "20231113T150300",
            "authors": [
                "Kinjel Shah"
            ],
            "summary": "Drug, biotech companies are likely to see significant innovation. In the Large-Cap Pharmaceuticals industry, Eli Lilly (LLY), Novo Nordisk (NVO), J&J (JNJ) and AbbVie (ABBV) are worth retaining in your portfolio.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/b2/19786.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.962106"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986564"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.179759,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.097954",
                    "ticker_sentiment_score": "0.099631",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.04907",
                    "ticker_sentiment_score": "0.092705",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KVUE",
                    "relevance_score": "0.04907",
                    "ticker_sentiment_score": "0.102773",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.146469",
                    "ticker_sentiment_score": "0.118959",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "0.108175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SGEN",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.024546",
                    "ticker_sentiment_score": "0.067704",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35751599/eli-lilly-unusual-options-activity",
            "time_published": "20231113T150130",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Deep-pocketed investors have adopted a bearish approach towards Eli Lilly LLY, and it's something market players shouldn't ignore. Our tracking of public options records at Benzinga unveiled this significant move today.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_0.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.114342,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.76367",
                    "ticker_sentiment_score": "0.095214",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer's top 10 things to watch in the stock market Monday",
            "url": "https://www.cnbc.com/2023/11/13/jim-cramers-top-10-things-to-watch-in-the-stock-market-monday.html",
            "time_published": "20231113T140135",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "U.S. stocks edge lower in premarket trading, while China is reportedly considering ending its freeze on Boeing (BA).",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107322414-1698238766344-max.jpg?v=1698238783&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.175907,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BURL",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.002474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRWD",
                    "relevance_score": "0.189175",
                    "ticker_sentiment_score": "0.220713",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CTVA",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.04598",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JPM",
                    "relevance_score": "0.063594",
                    "ticker_sentiment_score": "0.020362",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.02512",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "STZ",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.222515",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.189175",
                    "ticker_sentiment_score": "0.189752",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "-0.007238",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BA",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "0.093879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.126784",
                    "ticker_sentiment_score": "-0.006164",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Verve Therapeutics stock falls 40% as analysts question safety of cholesterol-cutting gene-editing treatment",
            "url": "https://www.marketwatch.com/story/verve-therapeutics-stock-falls-40-as-analysts-question-safety-of-cholesterol-cutting-gene-editing-treatment-2914a2bf",
            "time_published": "20231113T140100",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Analysts raise concerns about comparative effectiveness of experimental cholesterol treatment.",
            "banner_image": "https://images.mktw.net/im-886048/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.014381,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.032657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "0.032657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.232439",
                    "ticker_sentiment_score": "-0.047453",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "POINT Biopharma Reports Third Quarter 2023 Financial Results and Provides Business Highlights",
            "url": "https://www.globenewswire.com/news-release/2023/11/13/2778941/0/en/POINT-Biopharma-Reports-Third-Quarter-2023-Financial-Results-and-Provides-Business-Highlights.html",
            "time_published": "20231113T123000",
            "authors": [
                "POINT Biopharma"
            ],
            "summary": "Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per share in cash ( an aggregate of approximately $1.4 billion ). transaction expected to close near the end of 2023 Announced a definitive agreement to be acquired by Lilly for a purchase price of $12.50 per ...",
            "banner_image": "https://ml.globenewswire.com/Resource/Download/8b9200ff-b90a-4f3d-965f-7f0a8729aa2b",
            "source": "GlobeNewswire",
            "category_within_source": "n/a",
            "source_domain": "www.globenewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.992549"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.838487"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.9973"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.134391,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.218226",
                    "ticker_sentiment_score": "0.231825",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.132004",
                    "ticker_sentiment_score": "0.076126",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Should You Invest in the Vanguard Health Care ETF  ( VHT ) ?",
            "url": "https://www.zacks.com/stock/news/2183064/should-you-invest-in-the-vanguard-health-care-etf-vht",
            "time_published": "20231113T112005",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Sector ETF report for ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default15.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.244101,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.064321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SPGI",
                    "relevance_score": "0.067536",
                    "ticker_sentiment_score": "0.125774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.064321",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.064321",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Better Buy Now: Novo Nordisk vs. Eli Lilly",
            "url": "https://www.fool.com/investing/2023/11/13/better-buy-now-novo-nordisk-vs-eli-lilly/",
            "time_published": "20231113T111700",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Both of these companies are reporting positive news for their competing weight-loss drugs, but which is the better stock to buy now?",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754828%2Finvestors-evaluating-a-stock-purchase-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.18026,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.26928",
                    "ticker_sentiment_score": "0.145472",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.22574",
                    "ticker_sentiment_score": "0.2449",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.045743",
                    "ticker_sentiment_score": "0.029926",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.045743",
                    "ticker_sentiment_score": "0.029926",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Wegovy Weight Loss Drug Cuts Heart Complication Risk, Says Trial - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35738832/wegovy-weight-loss-drug-cuts-heart-complication-risk-says-trial",
            "time_published": "20231111T213359",
            "authors": [
                "Benzinga Neuro"
            ],
            "summary": "A clinical trial has revealed that Novo Nordisk's NVO weight loss drug Wegovy significantly decreases the risk of serious heart complications. According to CNBC, the Select study tested Wegovy on around 17,500 individuals with obesity and heart disease. These participants did not have diabetes.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/11/shutterstock_2338223569.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.087667,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.27432",
                    "ticker_sentiment_score": "0.391559",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.401331",
                    "ticker_sentiment_score": "0.316129",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "'Market's Had A Very Solid Winning Streak Of Late': Jim Cramer Eyes Key Retailers And CPI Data In Critical Earnings Week Ahead - Target  ( NYSE:TGT ) , Monday.Com  ( NASDAQ:MNDY ) , Novo Nordisk  ( NYSE:NVO ) , ServiceNow  ( NYSE:NOW ) ",
            "url": "https://www.benzinga.com/news/earnings/23/11/35738440/markets-had-a-very-solid-winning-streak-of-late-jim-cramer-eyes-key-retailers-and-cpi-data-in-criti",
            "time_published": "20231111T191808",
            "authors": [
                "Nabaparna Bhattacharya"
            ],
            "summary": "CNBC market analyst Jim Cramer emphasized the importance of the upcoming week for investors, spotlighting significant data and earnings reports due on Wall Street.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/11/shutterstock_730916710.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.905476"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.321595,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "TGT",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "-0.193667",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.288575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.115232",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.288575",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ACN",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HD",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "0.087309",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "M",
                    "relevance_score": "0.228073",
                    "ticker_sentiment_score": "-0.142726",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WMT",
                    "relevance_score": "0.33628",
                    "ticker_sentiment_score": "-0.193667",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Novo Nordisk's Wegovy cuts risk of heart attack and stroke by 20% among people without diabetes, study finds",
            "url": "https://www.marketwatch.com/story/novo-nordisks-wegovy-cuts-risk-of-heart-attack-and-stroke-by-20-among-people-without-diabetes-study-finds-00355d95",
            "time_published": "20231111T134700",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Closely watched clinical trial could help boost insurance coverage of GLP-1 drugs, analysts say.",
            "banner_image": "https://images.mktw.net/im-349237/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.038696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.220809",
                    "ticker_sentiment_score": "0.127559",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.263467",
                    "ticker_sentiment_score": "-0.054614",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Weight-loss drugs just got cheaper - and better",
            "url": "https://www.businessinsider.com/zepound-eli-lilly-weight-loss-drug-cost-cheaper-than-wegovy",
            "time_published": "20231111T114300",
            "authors": [
                "Hilary Brueck",
                "Shelby Livingston"
            ],
            "summary": "Eli Lilly's weight-loss drug Zepbound is cheaper than Wegovy - Business Insider ...",
            "banner_image": null,
            "source": "Business Insider",
            "category_within_source": "GoogleRSS",
            "source_domain": "www.businessinsider.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.055195,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.318382",
                    "ticker_sentiment_score": "0.059783",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.122269",
                    "ticker_sentiment_score": "-0.078184",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Cautious Investor? 2 Safe Stocks You Also Can Count on For Growth",
            "url": "https://www.fool.com/investing/2023/11/11/cautious-investor-2-safe-stocks-you-also-can-count/",
            "time_published": "20231111T100000",
            "authors": [
                "Adria Cimino"
            ],
            "summary": "These stocks offer the best of both worlds.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754495%2Fgettyimages-1253877215.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.98396"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.44085,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.2842",
                    "ticker_sentiment_score": "0.355549",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.058047",
                    "ticker_sentiment_score": "-0.059248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.207342",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Here's how Eli Lilly might bring a game-changing Alzheimer's drug to market",
            "url": "https://www.marketwatch.com/story/heres-how-eli-lilly-might-bring-a-game-changing-alzheimers-drug-to-market-6895dbc5",
            "time_published": "20231110T172100",
            "authors": [
                "Philip van Doorn"
            ],
            "summary": "Also: Bad and good results this earnings season, new tax rules, stock picks and how you too can be a mortgage lender.",
            "banner_image": "https://images.mktw.net/im-885116?width=700&height=634",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.967321"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": 0.016892,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "GOOG",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.146671",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.049921",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.051005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GRPN",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UA",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.156001",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "T",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.052464",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "U",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.069702",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "0.035336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.051005",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.017097",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RDFN",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.014175",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.058831",
                    "ticker_sentiment_score": "0.056382",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.029436",
                    "ticker_sentiment_score": "-0.049921",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Who's afraid of Ozempic? From restaurants to package makers, companies work to calm investors' GLP-1 jitters.",
            "url": "https://www.marketwatch.com/story/whos-afraid-of-ozempic-from-restaurants-to-package-makers-companies-work-to-calm-investors-glp-1-jitters-0599dba5",
            "time_published": "20231110T161300",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "With Eli Lilly's Zepbound set to enter the fray, companies are flooded with weight-loss drug questions ...",
            "banner_image": "https://images.mktw.net/im-884373/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.990678"
                }
            ],
            "overall_sentiment_score": 0.0,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "MDLZ",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.002046",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.024949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TFX",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.113802",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CCK",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.025973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.03176",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FMS",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.071582",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HSY",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.056973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BUD",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.046958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABT",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.07861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FSNUF",
                    "relevance_score": "0.025929",
                    "ticker_sentiment_score": "0.065219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.077677",
                    "ticker_sentiment_score": "0.025463",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KDP",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.010993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.024949",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DRI",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.162516",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "-0.054643",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CMG",
                    "relevance_score": "0.05183",
                    "ticker_sentiment_score": "0.119502",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Where Will Eli Lilly Be in 5 Years?",
            "url": "https://www.fool.com/investing/2023/11/10/where-will-eli-lilly-be-in-5-years/",
            "time_published": "20231110T152300",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "If management has its way, Eli Lilly's earnings and share price will be way up.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.614606"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.183459,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.320279",
                    "ticker_sentiment_score": "0.242431",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.054857",
                    "ticker_sentiment_score": "0.140999",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Widely Popular GLP-1-Based Weight Loss Drugs Reshape US Healthcare Landscape, May Help Control Addiction - Novo Nordisk  ( NYSE:NVO ) , Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35723209/widely-popular-glp-1-based-weight-loss-drugs-reshape-us-healthcare-landscape-may-help-control-add",
            "time_published": "20231110T140156",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Speakers at an event highlighted the impact of a new class of weight loss drugs, including substance abuse, on the U.S. healthcare system. Wednesday, the FDA approved Eli Lilly And Co's LLY Zepbound ( tirzepatide ) injection for obesity treatment.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/10/wegovy_.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.00239,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.264299",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.218996",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "WBA",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "0.032162",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "'I Want You To Buy It, And Every Time It Dips, I Want You To Buy More': Cramer Hypes Up Auto Parts Retailer - Aehr Test Systems  ( NASDAQ:AEHR ) , Agilent Technologies  ( NYSE:A ) ",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/11/35720773/i-want-you-to-buy-it-and-every-time-it-dips-i-want-you-to-buy-more-cramer-hypes-up-auto-",
            "time_published": "20231110T140142",
            "authors": [
                "Lisa Levin"
            ],
            "summary": "On CNBC's \"Mad Money Lightning Round,\" Jim Cramer said Broadcom Inc. AVGO is a \"buy.\" Cramer said although Novo Nordisk A/S NVO is \"very good,\" but he still prefers Eli Lilly and Company LLY. \"I want you to be owning either one of those,\" he added. Don't forget to check out our premarket ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/10/jim_cramer_nyse_shutter.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.796627"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                }
            ],
            "overall_sentiment_score": 0.098458,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AEHR",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "-0.136199",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "A",
                    "relevance_score": "0.115787",
                    "ticker_sentiment_score": "0.074709",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GOGO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "-0.114617",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AVGO",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "-0.335405",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.533481",
                    "ticker_sentiment_score": "0.138843",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.276645",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.374979",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DFH",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.130072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.337811",
                    "ticker_sentiment_score": "0.374979",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Top Funds Can't Get Enough Of Amazon - And This Intelligence Play",
            "url": "https://www.investors.com/etfs-and-funds/mutual-funds/amazon-stock-palantir-oracle-and-this-auctioneer-lead-list-of-new-buys-by-the-best-mutual-funds/",
            "time_published": "20231110T130100",
            "authors": [
                "MATTHEW GALGANI",
                "Investor's Business Daily"
            ],
            "summary": "Just in time for a Santa Claus rally and the holiday shopping season, the best mutual funds have placed a massive bet on online retailer and cloud giant Amazon.com ( AMZN ) . The latest list of new buys by top funds shows these savvy money managers scooped up a whopping $16.2 billion worth of ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-santapresents-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "IPO",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.219881,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BKR",
                    "relevance_score": "0.144275",
                    "ticker_sentiment_score": "-0.045344",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.28387",
                    "ticker_sentiment_score": "-0.14356",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RBA",
                    "relevance_score": "0.350564",
                    "ticker_sentiment_score": "0.15509",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.28387",
                    "ticker_sentiment_score": "0.219574",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FTI",
                    "relevance_score": "0.214937",
                    "ticker_sentiment_score": "-0.179902",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.586747",
                    "ticker_sentiment_score": "0.279753",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Market Rally Pauses As Yields Rebound: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-pauses-as-yields-rebound-datadog-affirm-among-earnings-winners-weekly-review/",
            "time_published": "20231110T120000",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "The stock market rally saw the Dow Jones, S&P 500 and Nasdaq snap long win streaks, slashing or erasing weekly gains. The Russell 2000 tumbled amid weak breadth. Earnings generally remained positive.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2017/01/INCOME_yield_013017_shutter.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.997405"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.166667"
                }
            ],
            "overall_sentiment_score": -0.017348,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "APP",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.091746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CELH",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.114644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FLYW",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.032924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TTD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.070037",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.075537",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DDOG",
                    "relevance_score": "0.162489",
                    "ticker_sentiment_score": "-0.016092",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOUR",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.032924",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AXON",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.161943",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "FN",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.060043",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DUOL",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.005589",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.006543",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DT",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.018995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "OXY",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.170289",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.077475",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FANG",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.170289",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "GFS",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TDG",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.02077",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.116461",
                    "ticker_sentiment_score": "0.016621",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AOSL",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MTSI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.093289",
                    "ticker_sentiment_score": "0.042954",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SNOW",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.018995",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NXPI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.006148",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BSY",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LCID",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "POWI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DIOD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PEP",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.114644",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.006",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARM",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.013948",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "0.073194",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AFRM",
                    "relevance_score": "0.116461",
                    "ticker_sentiment_score": "-0.038586",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.046724",
                    "ticker_sentiment_score": "-0.127835",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "0.006148",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.070036",
                    "ticker_sentiment_score": "-0.085312",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Stock-Split Stock Behind Ozempic and Wegovy Could Be Yours for Just $100",
            "url": "https://www.fool.com/investing/2023/11/10/the-stock-split-stock-behind-ozempic-and-wegovy-co/",
            "time_published": "20231110T115400",
            "authors": [
                "Adam Spatacco"
            ],
            "summary": "Novo Nordisk just reported financial and operating results through the first nine months of the year. One thing is clear: Demand is not an issue.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F753587%2Fa-doctor-writing-a-prescription.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.891286"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999997"
                }
            ],
            "overall_sentiment_score": 0.247377,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.135921",
                    "ticker_sentiment_score": "0.09358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.068209",
                    "ticker_sentiment_score": "0.076597",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.50649",
                    "ticker_sentiment_score": "0.335147",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.068209",
                    "ticker_sentiment_score": "0.076597",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?",
            "url": "https://www.fool.com/investing/2023/11/10/the-alzheimers-drug-market-is-heating-up-should-yo/",
            "time_published": "20231110T115000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "The real competitive battle is about to begin, and it will last a long time.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.684621"
                }
            ],
            "overall_sentiment_score": 0.217491,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18967",
                    "ticker_sentiment_score": "0.122235",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.235823",
                    "ticker_sentiment_score": "0.097212",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Look Out, Ozempic and Wegovy: Eli Lilly Has a New Weight-Loss Drug in Town",
            "url": "https://www.fool.com/investing/2023/11/10/look-out-ozempic-and-wegovy-eli-lilly-has-a-new-we/",
            "time_published": "20231110T104900",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Analysts predict Lilly's tirzepatide, marketed under the Mounjaro and Zepbound brands, could achieve peak annual sales of more than $50 billion.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.094742,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.424521",
                    "ticker_sentiment_score": "0.125861",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.368773",
                    "ticker_sentiment_score": "0.16364",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.251032",
                    "ticker_sentiment_score": "0.135461",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Was Hoping for 5 Big Drug Launches This Year. Here's How It Has Done Thus Far.",
            "url": "https://www.fool.com/investing/2023/11/10/eli-lilly-was-hoping-for-5-big-drug-launches-this/",
            "time_published": "20231110T104000",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Is the company on track to meet its targets for the year?",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                }
            ],
            "overall_sentiment_score": 0.332652,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.558244",
                    "ticker_sentiment_score": "0.510774",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Lilly's Strategic Branding Move For Weight Loss Drug Sets Stage For Long Term Success - Analyst - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35705775/lillys-strategic-branding-move-for-weight-loss-drug-sets-stage-for-long-term-success-analyst",
            "time_published": "20231109T184425",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "Wednesday, the FDA approved Eli Lilly And Co's LLY Zepbound ( tirzepatide ) injection, the first and only obesity treatment.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/09/zepbound.png?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.31388,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.459624",
                    "ticker_sentiment_score": "0.544359",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.240489",
                    "ticker_sentiment_score": "-0.095544",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Beam Therapeutics  ( BEAM )  Q3 Earnings & Revenues Beat Estimates",
            "url": "https://www.zacks.com/stock/news/2181878/beam-therapeutics-beam-q3-earnings-revenues-beat-estimates",
            "time_published": "20231109T180400",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Beam Therapeutics' (BEAM) third-quarter 2023 earnings and revenues surpass expectations. The company focuses on developing genome-editing candidate, BEAM-101.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/86/1981.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.986413"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.098887,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.719257",
                    "ticker_sentiment_score": "0.065189",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.263942",
                    "ticker_sentiment_score": "0.155939",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.314151",
                    "ticker_sentiment_score": "0.171554",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LGND",
                    "relevance_score": "0.314151",
                    "ticker_sentiment_score": "0.17605",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.053749",
                    "ticker_sentiment_score": "0.137734",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Why Eli Lilly Stock Is Slumping Today",
            "url": "https://www.fool.com/investing/2023/11/09/why-eli-lilly-stock-is-slumping-today/",
            "time_published": "20231109T160816",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Good news for Lilly is somehow translating to bad news for its share price.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.154953,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.769861",
                    "ticker_sentiment_score": "0.21387",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "The $2 Billion Bet AstraZeneca Is Making In Weight Loss",
            "url": "https://www.investors.com/news/technology/azn-stock-astrazeneca-earnings-q3-2023/",
            "time_published": "20231109T152800",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "AZN Stock Jumps On $2 Billion Bet In Weight-Loss Drugs Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/12/Stock-AstraZeneca-03-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.983783"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                }
            ],
            "overall_sentiment_score": 0.097418,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.18046",
                    "ticker_sentiment_score": "0.238014",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.828945",
                    "ticker_sentiment_score": "0.133769",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Healthcare Stocks That Have More Than Doubled in Value Since the Fed Started Raising Interest Rates",
            "url": "https://www.fool.com/investing/2023/11/09/3-healthcare-stocks-that-have-more-than-doubled/",
            "time_published": "20231109T152300",
            "authors": [
                "David Jagielski"
            ],
            "summary": "Can these promising growth stocks continue rising in value?",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995973"
                }
            ],
            "overall_sentiment_score": 0.358261,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.395012",
                    "ticker_sentiment_score": "0.468633",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "TMDX",
                    "relevance_score": "0.395012",
                    "ticker_sentiment_score": "0.340277",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AXSM",
                    "relevance_score": "0.175433",
                    "ticker_sentiment_score": "0.140973",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Has Yet Another Ozempic Killer in the Works. Is It a Screaming Buy?",
            "url": "https://www.fool.com/investing/2023/11/09/eli-lilly-ozempic-killer-in-works-bioage/",
            "time_published": "20231109T143556",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "This competition is leading to a lot of serious innovation.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": 0.141924,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.264419",
                    "ticker_sentiment_score": "0.01226",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.17813",
                    "ticker_sentiment_score": "0.181134",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Zacks Earnings Trends Highlights: Pfizer, Eli Lilly, General Motors and Tesla",
            "url": "https://www.zacks.com/stock/news/2181525/zacks-earnings-trends-highlights-pfizer-eli-lilly-general-motors-and-tesla",
            "time_published": "20231109T135000",
            "authors": [
                "Zacks Investment Research"
            ],
            "summary": "Pfizer, Eli Lilly, General Motors and Tesla have been highlighted in this Earnings Trends article.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/38/20242.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999999"
                }
            ],
            "overall_sentiment_score": 0.043493,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "-0.028304",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.188193",
                    "ticker_sentiment_score": "-0.028304",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "1 Cathie Wood Stock to Buy Hand Over Fist Right Now",
            "url": "https://www.fool.com/investing/2023/11/09/1-cathie-wood-stock-to-buy-hand-over-fist-right-no/",
            "time_published": "20231109T130000",
            "authors": [
                "George Budwell"
            ],
            "summary": "This next-generation gene therapy stock could be a big winner.",
            "banner_image": "https://media.ycharts.com/charts/763ebd7133c94dca9502277a0ba85129.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.961735"
                }
            ],
            "overall_sentiment_score": 0.239771,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.137671",
                    "ticker_sentiment_score": "0.116249",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.335367",
                    "ticker_sentiment_score": "0.353978",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.205225",
                    "ticker_sentiment_score": "0.195341",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "2 Growth Stocks That Already Jumped 50% in November and Could Keep Climbing Higher",
            "url": "https://www.fool.com/investing/2023/11/09/2-growth-stocks-that-jumped-up-more-than-50-last-w/",
            "time_published": "20231109T105700",
            "authors": [
                "Cory Renauer"
            ],
            "summary": "Recent gains could be the start of a longer bull run.",
            "banner_image": "https://g.foolcdn.com/image/?url=https%3A%2F%2Fg.foolcdn.com%2Feditorial%2Fimages%2F754292%2Fcouple-at-home-with-device-getty.jpg&op=resize&w=700",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.839681"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.214378"
                }
            ],
            "overall_sentiment_score": 0.279639,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.052112",
                    "ticker_sentiment_score": "0.08358",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.206245",
                    "ticker_sentiment_score": "0.050014",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TMDX",
                    "relevance_score": "0.527831",
                    "ticker_sentiment_score": "0.428868",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.398939",
                    "ticker_sentiment_score": "0.360258",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Earnings Estimates Come Under Pressure",
            "url": "https://www.zacks.com/commentary/2181217/earnings-estimates-come-under-pressure",
            "time_published": "20231108T232200",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/3b/649.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.026631,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "-0.029102",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "-0.029102",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Earnings Estimates Come Under Pressure",
            "url": "https://www.zacks.com/commentary/2181196/earnings-estimates-come-under-pressure",
            "time_published": "20231108T232000",
            "authors": [
                "Sheraz Mian"
            ],
            "summary": "While Q3 results have been better than expected, there is a notable acceleration in negative estimate revisions over the last few weeks, contrasting the largely favorable revisions trend of the preceding six months.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/37/20536.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.026631,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "-0.029102",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.195287",
                    "ticker_sentiment_score": "-0.029102",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Lilly Announces Extension of Tender Offer to Acquire POINT Biopharma",
            "url": "https://www.prnewswire.com/news-releases/lilly-announces-extension-of-tender-offer-to-acquire-point-biopharma-301982413.html",
            "time_published": "20231108T215600",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "INDIANAPOLIS, Nov. 8, 2023 /PRNewswire/ -- Eli Lilly and Company ( NYSE: LLY ) today announced the extension of the expiration of the tender offer to acquire all of the issued and outstanding shares ( \"Shares\" ) of common stock of POINT Biopharma Global Inc. ( NASDAQ: PNT ) , for a purchase ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.967645"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.999989"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.275223,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.43762",
                    "ticker_sentiment_score": "0.333851",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.033006",
                    "ticker_sentiment_score": "0.164977",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CMSQF",
                    "relevance_score": "0.033006",
                    "ticker_sentiment_score": "0.183218",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "PNT",
                    "relevance_score": "0.065957",
                    "ticker_sentiment_score": "0.064319",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly receives approval for its weight-loss drug. But here's what could boost the stock next",
            "url": "https://www.cnbc.com/2023/11/08/this-could-be-the-next-catalyst-for-eli-lilly-stock-.html",
            "time_published": "20231108T193946",
            "authors": [
                "Kevin Stankiewicz"
            ],
            "summary": "Shares of Eli Lilly jumped Wednesday after the U.S. gave the green light for the company's blockbuster GLP-1 drug to be used as an obesity treatment.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107261723-1687535077484-gettyimages-1302141489-cailly03.jpeg?v=1699466920&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": 0.358109,
            "overall_sentiment_label": "Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.930964",
                    "ticker_sentiment_score": "0.586547",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Weight Loss Drug Competition - FDA Approves Expanded Use Of Eli Lilly's Blockbuster Tirzepatide For Weight Loss, Undercutting Novo Nordisk's Price - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/general/biotech/23/11/35680340/weight-loss-drug-competition-fda-approves-expanded-use-of-eli-lillys-blockbuster-tirzepatide-for-",
            "time_published": "20231108T190403",
            "authors": [
                "Vandana Singh"
            ],
            "summary": "The FDA has approved Eli Lilly And Co's LLY Zepbound ( tirzepatide ) injection, the first and only obesity treatment of its kind that activates both GIP ( glucose-dependent insulinotropic polypeptide ) and GLP-1 ( glucagon-like peptide-1 ) hormone receptors.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/08/weight-loss-photo_by_vidmir_rais_via_pixabay.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "General",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.021498,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.412298",
                    "ticker_sentiment_score": "0.370849",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.143415",
                    "ticker_sentiment_score": "-0.177144",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly gets FDA approval for new obesity drug",
            "url": "https://www.marketwatch.com/story/eli-lilly-gets-fda-approval-for-new-obesity-drug-ef514794",
            "time_published": "20231108T182200",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Zepbound helped patients lose up to 48 pounds on average in clinical trials.",
            "banner_image": "https://images.mktw.net/im-735118/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                }
            ],
            "overall_sentiment_score": -0.03835,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.743214",
                    "ticker_sentiment_score": "-0.162992",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly Wins FDA Approval For Highly Anticipated Weight-Loss Drug",
            "url": "https://www.investors.com/news/technology/eli-lilly-stock-lilly-wins-fda-approval-for-highly-anticipated-weight-loss-drug/",
            "time_published": "20231108T174400",
            "authors": [
                "Investor's Business Daily",
                "ALLISON GATLIN"
            ],
            "summary": "The Food and Drug Administration approved a highly anticipated weight-loss drug from Eli Lilly ( LLY ) on Wednesday. The drug, which goes by the test name tirzepatide, is already approved as Mounjaro for patients with type 2 diabetes.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/10/Stock-EliLilly-03-shutt.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.538269"
                }
            ],
            "overall_sentiment_score": -0.052198,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.803061",
                    "ticker_sentiment_score": "0.064291",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "FDA Approves Lilly's Zepbound™  ( tirzepatide )  for Chronic Weight Management, a Powerful New Option for the Treatment of Obesity or Overweight with Weight-Related Medical Problems",
            "url": "https://www.prnewswire.com/news-releases/fda-approves-lillys-zepbound-tirzepatide-for-chronic-weight-management-a-powerful-new-option-for-the-treatment-of-obesity-or-overweight-with-weight-related-medical-problems-301982041.html",
            "time_published": "20231108T172200",
            "authors": [
                "Eli Lilly and Company"
            ],
            "summary": "FDA Approves Lilly's Zepbound™ ( tirzepatide ) for Chronic Weight Management, a Powerful New Option for the ... PR ...",
            "banner_image": "https://mma.prnewswire.com/media/133140/eli_lilly_and_company_logo.jpg?p=facebook",
            "source": "PR Newswire",
            "category_within_source": "n/a",
            "source_domain": "www.prnewswire.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.310843"
                }
            ],
            "overall_sentiment_score": -0.120251,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.188758",
                    "ticker_sentiment_score": "0.032688",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.014657",
                    "ticker_sentiment_score": "0.151969",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AWON",
                    "relevance_score": "0.029309",
                    "ticker_sentiment_score": "-0.00669",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Nektar Therapeutics  ( NKTR )  Incurs Wider-Than-Expected Q3 Loss",
            "url": "https://www.zacks.com/stock/news/2181024/nektar-therapeutics-nktr-incurs-wider-than-expected-q3-loss",
            "time_published": "20231108T164700",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Nektar (NKTR) misses third-quarter estimates for the bottom line but beats the same for the top line.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/f5/284.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.96136"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.033098,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.155451",
                    "ticker_sentiment_score": "-0.014417",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DVAX",
                    "relevance_score": "0.305058",
                    "ticker_sentiment_score": "0.167698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MEIP",
                    "relevance_score": "0.256179",
                    "ticker_sentiment_score": "0.150065",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NKTR",
                    "relevance_score": "0.486627",
                    "ticker_sentiment_score": "-0.141876",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Pharma ETFs in Focus Post Q3 Earnings",
            "url": "https://www.zacks.com/stock/news/2180987/pharma-etfs-in-focus-post-q3-earnings",
            "time_published": "20231108T161000",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "Many industry bigwigs reported solid results, with some beating on earnings or revenues or both.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/6e/37920.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999989"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.095657,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.150357",
                    "ticker_sentiment_score": "0.047923",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SKXJF",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "0.072219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DSKYF",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "0.072219",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.113062",
                    "ticker_sentiment_score": "0.048088",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.075516",
                    "ticker_sentiment_score": "-0.043588",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.150357",
                    "ticker_sentiment_score": "0.070615",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly Slashed Its Earnings Guidance and Its Stock Went Up 5% Anyway. What's Next?",
            "url": "https://www.fool.com/investing/2023/11/08/eli-lilly-slashed-its-earnings-guidance-and-its-st/",
            "time_published": "20231108T132000",
            "authors": [
                "Alex Carchidi"
            ],
            "summary": "Aggressive investments in growth have left the pharma giant with smaller profits this year.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.266143"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99246"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.255444,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.236972",
                    "ticker_sentiment_score": "0.248432",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.192043",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.060085",
                    "ticker_sentiment_score": "0.17703",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Grab these 2 funds with rich 11%-12% yields while you can",
            "url": "https://www.marketwatch.com/story/grab-these-2-funds-with-rich-11-12-yields-while-you-can-f2856fb2",
            "time_published": "20231108T121800",
            "authors": [
                "Michael Brush"
            ],
            "summary": "If you invest for income, consider taking advantage of these unusual opportunities.",
            "banner_image": "https://images.mktw.net/im-879591/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.166559,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BLK",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.232625",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "HESG",
                    "relevance_score": "0.045054",
                    "ticker_sentiment_score": "0.208956",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.166414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.166414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MORN",
                    "relevance_score": "0.045054",
                    "ticker_sentiment_score": "0.060686",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.13459",
                    "ticker_sentiment_score": "0.166414",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.089965",
                    "ticker_sentiment_score": "0.219686",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Unusual Options Activity - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35646341/eli-lilly-unusual-options-activity",
            "time_published": "20231107T150119",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bearish stance on Eli Lilly LLY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_5.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.929393"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.066696,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.877669",
                    "ticker_sentiment_score": "0.200316",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "-0.026742",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.102449",
                    "ticker_sentiment_score": "-0.137194",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( LLY )  is Attracting Investor Attention: Here is What You Should Know",
            "url": "https://www.zacks.com/stock/news/2179968/eli-lilly-and-company-lly-is-attracting-investor-attention-here-is-what-you-should-know",
            "time_published": "20231107T140011",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Lilly (LLY) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.",
            "banner_image": "https://staticx-tuner.zacks.com/images/default_article_images/default33.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999998"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.5855"
                }
            ],
            "overall_sentiment_score": 0.23135,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.529767",
                    "ticker_sentiment_score": "0.113399",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Humana, Eli Lilly And A Major Mining Stock On CNBC's 'Final Trades' - Humana  ( NYSE:HUM ) , Freeport-McMoRan  ( NYSE:FCX ) ",
            "url": "https://www.benzinga.com/trading-ideas/long-ideas/23/11/35636844/humana-eli-lilly-and-a-major-mining-stock-on-cnbcs-final-trades",
            "time_published": "20231107T135038",
            "authors": [
                "Lisa Levin"
            ],
            "summary": "On CNBC's \"Halftime Report Final Trades,\" Bryn Talkington of Requisite Capital Management named Freeport-McMoRan Inc. FCX, adding that she likes the stock here in the mid-30s. Freeport-McMoRan reported third-quarter revenue growth of 16.4% year-over-year to $5.82 billion, topping the consensus of ...",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/07/trader_shutter.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.684621"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.283844,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.70749",
                    "ticker_sentiment_score": "0.737406",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "HUM",
                    "relevance_score": "0.70749",
                    "ticker_sentiment_score": "0.414028",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "FCX",
                    "relevance_score": "0.70749",
                    "ticker_sentiment_score": "0.664989",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "VRTS",
                    "relevance_score": "0.207571",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "3 Ultra-Safe Dividend Stocks to Buy Hand Over Fist in November",
            "url": "https://www.fool.com/investing/2023/11/07/3-ultra-safe-dividend-stocks-to-buy-hand-over-fist/",
            "time_published": "20231107T115900",
            "authors": [
                "George Budwell"
            ],
            "summary": "These three blue chips ought to be reliable, long-term income generators.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.714479"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.285064,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "KO",
                    "relevance_score": "0.364275",
                    "ticker_sentiment_score": "0.49306",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.306963",
                    "ticker_sentiment_score": "0.174211",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "XOM",
                    "relevance_score": "0.247838",
                    "ticker_sentiment_score": "0.190692",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FOREX:USD",
                    "relevance_score": "0.062926",
                    "ticker_sentiment_score": "-0.011203",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "These Are The 5 Top S&P 500 Performers Today",
            "url": "https://www.investors.com/news/sp-500-eli-lilly-among-top-performers-monday/",
            "time_published": "20231106T212100",
            "authors": [
                "Investor's Business Daily",
                "ED CARSON"
            ],
            "summary": "S&P 500: Eli Lilly, Power Generators Lead Top Performers Monday Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2018/04/stock-Eli-Lilly-01-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.316726"
                }
            ],
            "overall_sentiment_score": -0.036685,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "BAC",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "-0.1561",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "CEG",
                    "relevance_score": "0.185781",
                    "ticker_sentiment_score": "-0.027555",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "D",
                    "relevance_score": "0.124486",
                    "ticker_sentiment_score": "0.029698",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PARA",
                    "relevance_score": "0.245959",
                    "ticker_sentiment_score": "-0.189767",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "BNTX",
                    "relevance_score": "0.245959",
                    "ticker_sentiment_score": "0.121294",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "0.07422",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SEDG",
                    "relevance_score": "0.304679",
                    "ticker_sentiment_score": "-0.347763",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "NCLH",
                    "relevance_score": "0.245959",
                    "ticker_sentiment_score": "-0.152669",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.062434",
                    "ticker_sentiment_score": "-0.234378",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "ALB",
                    "relevance_score": "0.361626",
                    "ticker_sentiment_score": "-0.432338",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.245959",
                    "ticker_sentiment_score": "0.098865",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CNC",
                    "relevance_score": "0.185781",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MRNA",
                    "relevance_score": "0.185781",
                    "ticker_sentiment_score": "0.03801",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BKNG",
                    "relevance_score": "0.361626",
                    "ticker_sentiment_score": "0.138421",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "What Happened With Eli Lilly and Company Stock Today? - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/11/35629456/what-happened-with-eli-lilly-and-company-stock-today",
            "time_published": "20231106T212050",
            "authors": [
                "Ryan Gustafson"
            ],
            "summary": "Eli Lilly and Company LLY shares traded higher on Monday. The stock has been trending higher since the company reported third-quarter earnings. What To Know: Eli Lilly posted third-quarter financial results on Nov. 2 before the open of the market.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/06/medicine-8287535_12803.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "News",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.172618,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.958533",
                    "ticker_sentiment_score": "0.32459",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.229149",
                    "ticker_sentiment_score": "-0.15635",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "The doctor lowering drug prices for 1 million patients, with help from Mark Cuban, Sam Altman - and Martin Shkreli",
            "url": "https://www.marketwatch.com/story/the-doctor-lowering-drug-prices-for-1-million-patients-with-help-from-mark-cuban-sam-altman-and-martin-shkreli-5e72d77a",
            "time_published": "20231106T203200",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Kristopher Koeller relies on two daily medications to keep his blood pressure under control. They're both generics that have been on the market for decades-the kind of drugs that should be cheap.",
            "banner_image": "https://images.mktw.net/im-871045?width=700&height=393",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.066744,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "CVS",
                    "relevance_score": "0.055848",
                    "ticker_sentiment_score": "-0.013012",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AZN",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.088489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.024774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.088489",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CHRS",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.007658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.041901",
                    "ticker_sentiment_score": "0.007958",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.007658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.007658",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "0.024774",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UNH",
                    "relevance_score": "0.027941",
                    "ticker_sentiment_score": "-0.042172",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Magnificent Seven Stocks Ignite New Rally - And These Buy Points",
            "url": "https://www.investors.com/research/how-to-find-the-best-stocks-to-buy/magnificent-seven-stocks-ignite-new-rally-buy-points-in-amazon-stock-nvidia-dkng-and-more/",
            "time_published": "20231106T184300",
            "authors": [
                "Investor's Business Daily",
                "MATTHEW GALGANI"
            ],
            "summary": "The Magnificent Seven stocks - Alphabet ( GOOGL ) , Amazon ( AMZN ) , Apple ( AAPL ) , Meta Platforms ( META ) , Microsoft ( MSFT ) , Nvidia ( NVDA ) and Tesla ( TSLA ) - continue to drive the new market rally.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/11/Stock-greenishbull-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.9545"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                }
            ],
            "overall_sentiment_score": 0.290351,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.074998",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.198493",
                    "ticker_sentiment_score": "0.124461",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.262522",
                    "ticker_sentiment_score": "0.145885",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.38489",
                    "ticker_sentiment_score": "0.257561",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.1331",
                    "ticker_sentiment_score": "0.096124",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.1331",
                    "ticker_sentiment_score": "0.096124",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.1331",
                    "ticker_sentiment_score": "0.060657",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.1331",
                    "ticker_sentiment_score": "0.239698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ZS",
                    "relevance_score": "0.1331",
                    "ticker_sentiment_score": "0.239698",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "AMZN",
                    "relevance_score": "0.549265",
                    "ticker_sentiment_score": "0.347422",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "OLLI",
                    "relevance_score": "0.198493",
                    "ticker_sentiment_score": "0.249764",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "$100 Invested In This Stock 5 Years Ago Would Be Worth $500 Today - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/news/23/11/35625630/100-invested-in-this-stock-5-years-ago-would-be-worth-500-today",
            "time_published": "20231106T173022",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Eli Lilly LLY has outperformed the market over the past 5 years by 30.05% on an annualized basis producing an average annual return of 39.45%. Currently, Eli Lilly has a market capitalization of $561.67 billion.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/valuestock_image_4.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Trading",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                }
            ],
            "overall_sentiment_score": 0.158543,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.980595",
                    "ticker_sentiment_score": "0.375984",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly chief scientific officer 'extremely optimistic' that major new Alzheimer's breakthrough is coming",
            "url": "https://www.marketwatch.com/story/eli-lilly-chief-scientific-officer-extremely-optimistic-that-major-new-alzheimers-breakthrough-is-coming-79003fcc",
            "time_published": "20231106T160500",
            "authors": [
                "Eleanor Laise"
            ],
            "summary": "Dr. Daniel Skovronsky believes a big leap in Alzheimer's disease treatment may be just around the corner-and that an overlooked class of medicines could become the GLP-1 drugs of the future. If he's right, Eli Lilly & Co.'s LLY, remarkable winning streak won't fizzle any time soon.",
            "banner_image": "https://images.mktw.net/im-857606/social",
            "source": "MarketWatch",
            "category_within_source": "Top Stories",
            "source_domain": "www.marketwatch.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.77141"
                }
            ],
            "overall_sentiment_score": 0.125979,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.365524",
                    "ticker_sentiment_score": "0.148178",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ESALF",
                    "relevance_score": "0.075754",
                    "ticker_sentiment_score": "0.013501",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.113418",
                    "ticker_sentiment_score": "0.152012",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BIIB",
                    "relevance_score": "0.075754",
                    "ticker_sentiment_score": "0.013501",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "JNJ",
                    "relevance_score": "0.075754",
                    "ticker_sentiment_score": "0.154848",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Cathie Wood's ARKK Had Its Best Week Due To 11 Huge Winners",
            "url": "https://www.investors.com/news/cathie-wood-ark-innovation-just-had-its-best-week-ever-thanks-to-11-huge-winners/",
            "time_published": "20231106T124500",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Cathie Wood's Ark Innovation ETF ( ARKK ) typically outpaces the overall market to the upside and downside. Last week, the S&P 500, Dow Jones and Nasdaq had their best gains of 2023. But the Ark Innovation ETF had its best week ever, up 18.6%. Credit massive moves among key components.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2021/11/Stock-CathieWoods-company.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995973"
                }
            ],
            "overall_sentiment_score": 0.216493,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "BEAM",
                    "relevance_score": "0.185543",
                    "ticker_sentiment_score": "0.068227",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.275177",
                    "ticker_sentiment_score": "0.089746",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.215757",
                    "ticker_sentiment_score": "-0.055256",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROKU",
                    "relevance_score": "0.275177",
                    "ticker_sentiment_score": "0.342629",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.155051",
                    "ticker_sentiment_score": "0.120388",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.124325",
                    "ticker_sentiment_score": "0.149851",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.062352",
                    "ticker_sentiment_score": "0.27244",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VERV",
                    "relevance_score": "0.185543",
                    "ticker_sentiment_score": "0.121474",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.245649",
                    "ticker_sentiment_score": "0.080792",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SQ",
                    "relevance_score": "0.124325",
                    "ticker_sentiment_score": "-0.128882",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NTLA",
                    "relevance_score": "0.09341",
                    "ticker_sentiment_score": "-0.024447",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.185543",
                    "ticker_sentiment_score": "0.085341",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRYPTO:BTC",
                    "relevance_score": "0.062352",
                    "ticker_sentiment_score": "0.19217",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "MBCC: Diversify Your Portfolio With These 3 Large Cap ETFs",
            "url": "https://stocknews.com/news/mbcc-voo-gvip-diversify-your-portfolio-with-these-3-large-cap-etfs/",
            "time_published": "20231106T115116",
            "authors": [
                "StockNews.com Staff"
            ],
            "summary": "MBCC: Diversify Your Portfolio With These 3 Large Cap ...",
            "banner_image": "https://stocknews.com/wp-content/uploads/2021/07/shutterstock_276782663-1-scaled.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "stocknews.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.166667"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.818451"
                }
            ],
            "overall_sentiment_score": 0.179383,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.08687",
                    "ticker_sentiment_score": "0.111289",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVDA",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.143993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.143993",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.08807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VST",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.042011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.08807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NKE",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.08807",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "VRT",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.042011",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GS",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.124106",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PANW",
                    "relevance_score": "0.057977",
                    "ticker_sentiment_score": "0.042011",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Eli Lilly and Company  ( NYSE:LLY )  Rating Increased to Buy at StockNews.com",
            "url": "https://www.defenseworld.net/2023/11/05/eli-lilly-and-company-nyselly-rating-increased-to-buy-at-stocknews-com.html",
            "time_published": "20231105T065846",
            "authors": [
                "Defense World Staff"
            ],
            "summary": "Eli Lilly and Company ( NYSE:LLY ) Rating Increased to Buy at ... Defense World ...",
            "banner_image": "https://www.marketbeat.com/logos/logo_eli_lilly.jpg",
            "source": "Stocknews.com",
            "category_within_source": "n/a",
            "source_domain": "www.defenseworld.net",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.961735"
                },
                {
                    "topic": "Mergers & Acquisitions",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.283079,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "GS",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.043973",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.826537",
                    "ticker_sentiment_score": "0.463085",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "JEF",
                    "relevance_score": "0.043421",
                    "ticker_sentiment_score": "0.043973",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Fed Holds Rates Steady, Powell's Cautious Stance Soothes Investors, Labor Market Softens: The Week In The Markets - Apple  ( NASDAQ:AAPL ) , Advanced Micro Devices  ( NASDAQ:AMD ) ",
            "url": "https://www.benzinga.com/markets/equities/23/11/35601229/fed-holds-rates-steady-powells-cautious-stance-soothes-investors-labor-market-softens-the-week-i",
            "time_published": "20231103T200339",
            "authors": [
                "Piero Cingari"
            ],
            "summary": "Markets bounced back decisively this week, shrugging off prior volatile months marked by heightened geopolitical tensions. The resurgence of risk sentiment ignited a relief rally in both equities and bonds, with investors embracing the Federal Reserve's decision to hold steady on interest rates.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/11/03/shutterstock_176534375.jpg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.890401"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.108179"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.25"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.99737"
                }
            ],
            "overall_sentiment_score": 0.135775,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "OXY",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.192694",
                    "ticker_sentiment_score": "0.209739",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.364054",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.185591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "BDX",
                    "relevance_score": "0.064797",
                    "ticker_sentiment_score": "-0.080072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.364054",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "0.185591",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GILD",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.129168",
                    "ticker_sentiment_score": "-0.093536",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Market Rally Back In Force As Yields Plunge: Weekly Review",
            "url": "https://www.investors.com/news/stock-market-rally-back-in-force-as-treasury-yields-plunge-arista-palantir-are-winners/",
            "time_published": "20231103T165559",
            "authors": [
                "Investor's Business Daily",
                "IBD STAFF"
            ],
            "summary": "The stock market rally took off this past week as Treasury yields plunged on generally weak economic data and soothing words from Fed Chief Jerome Powell Nasdaq staged a follow-through day to confirm the market rally on Wednesday, with the S&P 500 and Dow Jones following through on Thursday.",
            "banner_image": "https://www.investors.com/wp-content/uploads/2020/04/Stock-bullfightingbear-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Energy & Transportation",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Economy - Fiscal",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999897"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.142857"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Real Estate & Construction",
                    "relevance_score": "0.142857"
                }
            ],
            "overall_sentiment_score": 0.004916,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "XPEV",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROKU",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "0.015254",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "-0.061816",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ANET",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.040029",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LSCC",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SRPT",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.124905",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.078879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMGN",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.044243",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.352867",
                    "ticker_sentiment_label": "Bearish"
                },
                {
                    "ticker": "ALGM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MSFT",
                    "relevance_score": "0.070882",
                    "ticker_sentiment_score": "-0.040517",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.158635",
                    "ticker_sentiment_score": "-0.062061",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CRUS",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.044087",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QCOM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AMD",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "0.057142",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.078879",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PINS",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.028361",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "HMC",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.022873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ON",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "0.107",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "PLTR",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "-0.014717",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.024925",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.106148",
                    "ticker_sentiment_score": "-0.0443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "GM",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "-0.021613",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "RELY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.006008",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SMCI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.147308",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COR",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "0.167262",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "VRTX",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.15563",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ORCL",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.001911",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CBOE",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.13248",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CAH",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.16532",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CCJ",
                    "relevance_score": "0.088537",
                    "ticker_sentiment_score": "0.001072",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MELI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.019707",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MCK",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.16532",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ETSY",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.020024",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.136003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NIO",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TM",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.022873",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ARGX",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.053192",
                    "ticker_sentiment_score": "-0.136003",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "QRVO",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.11532",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "REGN",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "0.043443",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LI",
                    "relevance_score": "0.035476",
                    "ticker_sentiment_score": "-0.060946",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FOREX:JPY",
                    "relevance_score": "0.017742",
                    "ticker_sentiment_score": "-0.021613",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Check Out What Whales Are Doing With LLY - Eli Lilly  ( NYSE:LLY ) ",
            "url": "https://www.benzinga.com/markets/options/23/11/35596155/check-out-what-whales-are-doing-with-lly",
            "time_published": "20231103T163034",
            "authors": [
                "Benzinga Insights"
            ],
            "summary": "Someone with a lot of money to spend has taken a bearish stance on Eli Lilly LLY. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don't know.",
            "banner_image": "https://cdn.benzinga.com/files/images/story/2023/movers_image_1.jpeg?width=1200&height=800&fit=crop",
            "source": "Benzinga",
            "category_within_source": "Markets",
            "source_domain": "www.benzinga.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.316726"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.5"
                }
            ],
            "overall_sentiment_score": 0.109292,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.768168",
                    "ticker_sentiment_score": "-0.031531",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "C",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "WFC",
                    "relevance_score": "0.086556",
                    "ticker_sentiment_score": "-0.11944",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "MS",
                    "relevance_score": "0.172097",
                    "ticker_sentiment_score": "-0.160872",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                }
            ]
        },
        {
            "title": "Eli Lilly Beats on Q3 Earnings: ETFs to Buy",
            "url": "https://www.zacks.com/stock/news/2178224/eli-lilly-beats-on-q3-earnings-etfs-to-buy",
            "time_published": "20231103T150500",
            "authors": [
                "Sweta Killa"
            ],
            "summary": "Eli Lilly (LLY) posted robust third-quarter 2023 earnings results, beating estimates on both the top and bottom lines. Its Mounjaro anti-obesity drug continued its robust performance.",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/fc/588.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.904684"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999965"
                }
            ],
            "overall_sentiment_score": 0.251672,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.354952",
                    "ticker_sentiment_score": "0.326152",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                }
            ]
        },
        {
            "title": "Eli Lilly Just Added Another Potential Billion-Dollar Product: Is It a Buy?",
            "url": "https://www.fool.com/investing/2023/11/03/eli-lilly-just-added-another-potential-billion/",
            "time_published": "20231103T134500",
            "authors": [
                "Prosper Junior Bakiny"
            ],
            "summary": "The answer is relatively clear.",
            "banner_image": "https://media.ycharts.com/charts/9c3f474fdbe7c0a502a6d65cb8316359.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Earnings",
                    "relevance_score": "0.360215"
                },
                {
                    "topic": "Life Sciences",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                }
            ],
            "overall_sentiment_score": 0.312241,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.679765",
                    "ticker_sentiment_score": "0.439171",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "PFE",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.111724",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ABBV",
                    "relevance_score": "0.072",
                    "ticker_sentiment_score": "0.111724",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Jim Cramer's top 10 things to watch in the stock market Friday",
            "url": "https://www.cnbc.com/2023/11/03/jim-cramers-top-10-things-to-watch-in-the-stock-market-friday.html",
            "time_published": "20231103T131615",
            "authors": [
                "Jim Cramer"
            ],
            "summary": "U.S. stocks climb higher in premarket trading Friday, as employment growth slows in October.",
            "banner_image": "https://image.cnbcfm.com/api/v1/image/107328239-1698967149761-gettyimages-1760543444-AFP_33ZR2GX.jpeg?v=1698967981&w=1920&h=1080",
            "source": "CNBC",
            "category_within_source": "Top News",
            "source_domain": "www.cnbc.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Economy - Monetary",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.999612"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.060538,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.016245",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "BCS",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.013336",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TJX",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.046423",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.051902",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "-0.127897",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "0.193369",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "ROST",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "0.046423",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "SWKS",
                    "relevance_score": "0.113329",
                    "ticker_sentiment_score": "-0.057772",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "UBER",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "-0.115078",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CLX",
                    "relevance_score": "0.169279",
                    "ticker_sentiment_score": "-0.084688",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Company News for Nov 03, 2023",
            "url": "https://www.zacks.com/stock/news/2178063/company-news-for-nov-03-2023",
            "time_published": "20231103T123200",
            "authors": [
                "Zacks Equity Research"
            ],
            "summary": "Companies In The Article: LLY, SBUX, SHOP, ...",
            "banner_image": "https://staticx-tuner.zacks.com/images/articles/main/5a/2120.jpg",
            "source": "Zacks Commentary",
            "category_within_source": "n/a",
            "source_domain": "www.zacks.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.333333"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.451494"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.333333"
                }
            ],
            "overall_sentiment_score": 0.197521,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.219943",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.275993",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "CYBR",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.308198",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "SBUX",
                    "relevance_score": "0.608634",
                    "ticker_sentiment_score": "0.36078",
                    "ticker_sentiment_label": "Bullish"
                }
            ]
        },
        {
            "title": "Tech Futures Fall On Apple's Holiday Warning",
            "url": "https://www.investors.com/market-trend/stock-market-today/dow-jones-futures-apple-falls-on-holiday-outlook-jobs-report-due/",
            "time_published": "20231103T115257",
            "authors": [
                "ED CARSON",
                "Investor's Business Daily"
            ],
            "summary": "Dow Jones Futures: Apple Falls On Holiday Outlook. Jobs Report Due Investor's Business Daily ...",
            "banner_image": "https://www.investors.com/wp-content/uploads/2023/02/Stock-lion-closeup-01-adobe.jpg",
            "source": "Investors Business Daily",
            "category_within_source": "n/a",
            "source_domain": "www.investors.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Finance",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Blockchain",
                    "relevance_score": "0.310843"
                },
                {
                    "topic": "Retail & Wholesale",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "1.0"
                },
                {
                    "topic": "Manufacturing",
                    "relevance_score": "0.2"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.999892"
                }
            ],
            "overall_sentiment_score": 0.081629,
            "overall_sentiment_label": "Neutral",
            "ticker_sentiment": [
                {
                    "ticker": "DKNG",
                    "relevance_score": "0.065625",
                    "ticker_sentiment_score": "0.118196",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "META",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "ROKU",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.139678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "AAPL",
                    "relevance_score": "0.237288",
                    "ticker_sentiment_score": "-0.053779",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "IVZ",
                    "relevance_score": "0.021897",
                    "ticker_sentiment_score": "0.111303",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "DASH",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.139678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "COIN",
                    "relevance_score": "0.109157",
                    "ticker_sentiment_score": "-0.030444",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "KTOS",
                    "relevance_score": "0.065625",
                    "ticker_sentiment_score": "-0.192494",
                    "ticker_sentiment_label": "Somewhat-Bearish"
                },
                {
                    "ticker": "SHOP",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.139678",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TSLA",
                    "relevance_score": "0.021897",
                    "ticker_sentiment_score": "0.210413",
                    "ticker_sentiment_label": "Somewhat-Bullish"
                },
                {
                    "ticker": "FTNT",
                    "relevance_score": "0.087424",
                    "ticker_sentiment_score": "-0.088869",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NOW",
                    "relevance_score": "0.021897",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "LLY",
                    "relevance_score": "0.109157",
                    "ticker_sentiment_score": "0.122039",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "CVNA",
                    "relevance_score": "0.065625",
                    "ticker_sentiment_score": "-0.102509",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "YELP",
                    "relevance_score": "0.043778",
                    "ticker_sentiment_score": "0.0",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "TEAM",
                    "relevance_score": "0.065625",
                    "ticker_sentiment_score": "-0.102509",
                    "ticker_sentiment_label": "Neutral"
                },
                {
                    "ticker": "NET",
                    "relevance_score": "0.087424",
                    "ticker_sentiment_score": "-0.088869",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        },
        {
            "title": "Ozempic Sales Soar 56% in Q3. But Is Eli Lilly a Better Stock to Buy Than Novo Nordisk?",
            "url": "https://www.fool.com/investing/2023/11/03/ozempic-sales-soar-eli-lilly-better-stock-buy/",
            "time_published": "20231103T095100",
            "authors": [
                "Keith Speights"
            ],
            "summary": "Lilly's Mounjaro is gaining ground on Novo Nordisk's Ozempic.",
            "banner_image": "https://g.foolcdn.com/misc-assets/hp-sa-cumulative-growth-chart.png",
            "source": "Motley Fool",
            "category_within_source": "n/a",
            "source_domain": "www.fool.com",
            "topics": [
                {
                    "topic": "Life Sciences",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Financial Markets",
                    "relevance_score": "0.161647"
                },
                {
                    "topic": "Earnings",
                    "relevance_score": "0.995921"
                },
                {
                    "topic": "Technology",
                    "relevance_score": "0.5"
                },
                {
                    "topic": "Economy - Macro",
                    "relevance_score": "0.158519"
                }
            ],
            "overall_sentiment_score": 0.281598,
            "overall_sentiment_label": "Somewhat-Bullish",
            "ticker_sentiment": [
                {
                    "ticker": "LLY",
                    "relevance_score": "0.584822",
                    "ticker_sentiment_score": "0.510244",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "NVO",
                    "relevance_score": "0.395903",
                    "ticker_sentiment_score": "0.420562",
                    "ticker_sentiment_label": "Bullish"
                },
                {
                    "ticker": "DICE",
                    "relevance_score": "0.059049",
                    "ticker_sentiment_score": "0.030302",
                    "ticker_sentiment_label": "Neutral"
                }
            ]
        }
    ]
}